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Prostate-specific antigen (PSA) is a marker that is commonly used in estimating prostate 
cancer risk. Prostate cancer is usually a slowly progressing disease, which might not cause 
any symptoms whatsoever. Nevertheless, some cases of cancer are aggressive and need to 
be treated before they become life-threatening. However, the blood PSA concentration 
may rise also in benign prostate diseases and using a single total PSA (tPSA) 
measurement to guide the decision on further examinations leads to many unnecessary 
biopsies, over-detection, and overtreatment of indolent cancers which would not require 
treatment. Therefore, there is a need for markers that would better separate cancer from 
benign disorders, and would also predict cancer aggressiveness. The aim of this study was 
to evaluate whether intact and nicked forms of free PSA (fPSA-I and fPSA-N) or human 
kallikrein-related peptidase 2 (hK2) could serve as new tools in estimating prostate cancer 
risk. 
First, the immunoassays for fPSA-I and free and total hK2 were optimized so that they 
would be less prone to assay interference caused by interfering factors present in some 
blood samples. The optimized assays were shown to work well and were used to study the 
marker concentrations in the clinical sample panels. 
The marker levels were measured from preoperative blood samples of prostate cancer 
patients scheduled for radical prostatectomy. The association of the markers with the 
cancer stage and grade was studied. It was found that among all tested markers and their 
combinations especially the ratio of fPSA-N to tPSA and ratio of free PSA (fPSA) to 
tPSA were associated with both cancer stage and grade. They might be useful in 
predicting the cancer aggressiveness, but further follow-up studies are necessary to fully 
evaluate the significance of the markers in this clinical setting. 
The markers tPSA, fPSA, fPSA-I and hK2 were combined in a statistical model which 
was previously shown to be able to reduce unnecessary biopsies when applied to large 
screening cohorts of men with elevated tPSA. The discriminative accuracy of this model 
was compared to models based on established clinical predictors in reference to biopsy 
outcome. The kallikrein model and the calculated fPSA-N concentrations (fPSA minus 
fPSA-I) correlated with the prostate volume and the model, when compared to the clinical 
models, predicted prostate cancer in biopsy equally well. Hence, the measurement of 
kallikreins in a blood sample could be used to replace the volume measurement which is 
time-consuming, needs instrumentation and skilled personnel and is an uncomfortable 
procedure. Overall, the model could simplify the estimation of prostate cancer risk.  
Finally, as the fPSA-N seems to be an interesting new marker, a direct immunoassay for 
measuring fPSA-N concentrations was developed. The analytical performance was 
acceptable, but the rather complicated assay protocol needs to be improved until it can be 




In conclusion, by combining different markers it is possible to enhance the prostate cancer 






Joka vuosi tuhannet miehet Suomessa ja muualla maailmassa sairastuvat 
eturauhassyöpään, joka on Suomessa ja monessa muussa länsimaassa miesten yleisin 
syöpä. Eturauhassyöpä aiheuttaa paitsi huolta ja tuskaa kantajalleen myös merkittävät 
kustannukset terveydenhuoltojärjestelmälle. Eturauhassyöpä on yleensä hitaasti etenevä, 
eivätkä kaikki syövät aiheuta koskaan oireita. Osa syövistä kuitenkin etenee nopeasti ja 
voi lopulta aiheuttaa jopa kuoleman. Näiden syöpien löytyminen mahdollisimman 
varhaisessa vaiheessa on tärkeää, jotta hoito olisi tehokasta. 
Prostata-spesifinen antigeeni (PSA) on verenkierrossa oleva proteiini, jota käytetään 
yleisesti biomerkkiaineena eturauhassyövän riskin arvioinnissa. Veren PSA-taso voi 
kuitenkin nousta myös muissa eturauhasen sairauksissa. Jos yksittäisen kokonais-PSA-
määrityksen (tPSA) perusteella päätetään jatkotutkimuksista, seurauksena on monien 
turhien koepalojen otto, oireettomien hitaasti kasvavien syöpien löytyminen 
(ylidiagnostiikka) sekä turha hoito (ylihoito). On siis olemassa tarve biomerkkiaineelle, 
joka auttaisi erottamaan syövän muista eturauhasen sairauksista ja toisaalta hitaasti 
kasvavat syövät aggressiivista syövistä. Tämän tutkimuksen tarkoituksena oli selvittää, 
voitaisiinko vapaan PSA:n (fPSA) eri muotoja (ehjä fPSA eli fPSA-I ja sisäisesti 
pilkkoutunut fPSA eli fPSA-N) tai ihmisen kallikreiinin kaltaista peptidaasi 2:ta (hK2) 
hyödyntää eturauhassyövän riskin arvioinnissa. 
Immunomääritysten, joilla fPSA-I- ja hK2-määriä mitataan, todettiin olevan herkkiä 
verinäytteissä oleville erilaisille häiritseville tekijöille ja vaativan kehittämistä. Tehtyjen 
parannusten jälkeen määritykset toimivat hyvin, ja niitä voitiin käyttää kliinisten 
näytteiden biomerkkiainepitoisuuksien mittaamiseen. 
Biomerkkiaineiden pitoisuudet mitattiin eturauhasen poistoleikkaukseen menossa olevilta 
eturauhassyöpäpotilailta ennen leikkausta otetuista verinäytteistä. Pitoisuuksia verrattiin 
syövän levinneisyysasteeseen ja pahanlaatuisuuteen. Biomerkkiaineista ja niiden suhteista 
erityisesti fPSA-N:n ja tPSA:n suhde sekä fPSA:n ja tPSA:n suhde olivat yhteydessä 
syövän levinneisyyteen ja pahanlaatuisuuteen. Nämä pitoisuudet ja suhteet saattaisivat 
auttaa syövän aggressiivisuuden arvioinnissa, mutta tarvitaan laajempia 
seurantatutkimuksia, jotta niiden todellinen kliininen arvo voidaan todeta. 
Biomerkkiaineista tPSA, fPSA, fPSA-I ja hK2 on aikaisemmin yhdistetty tilastolliseen 
malliin, jonka avulla voitaisiin vähentää turhien koepalojen ottamista miehiltä, joilla on 
kohonnut tPSA-taso. Tässä väitöskirjatutkimuksessa edellä mainitun kallikreiinimallin 
kykyä ennustaa syövän läsnäolo koepaloissa verrattiin malleihin, joissa oli mukana 
nykykäytännön mukaisia kliinisiä tietoja. Kallikreiinimalli ja laskennallinen fPSA-N-
pitoisuus (fPSA – fPSA-I = fPSA-N) korreloivat eturauhasen tilavuuden kanssa, ja 
kallikreiinimalli myös ennusti syövän läsnäolon koepaloissa yhtä hyvin kuin kliinisiä 
tietoja sisältävä malli. Täten verinäytteestä tehtävät biomerkkiainemääritykset voisivat 
korvata ultraäänen avulla tehtävän eturauhasen tilavuuden mittaamisen, joka vaatii 




Kaiken kaikkiaan näiden biomerkkiaineiden mittaaminen voisi yksinkertaistaa 
eturauhassyövän riskin ennustamista. 
Koska fPSA-N osoittautui kiinnostavaksi biomerkkiaineeksi, kehitettiin immunomääritys 
sen mittaamiseksi verinäytteistä suoraan sen sijaan, että pitoisuus olisi määritetty 
laskennallisesti muiden määritysten tuloksista. Määritys toimi hyvin, mutta sen 
suorittaminen on jossain määrin monimutkaista, joten määritys tarvitsee kehittämistä 
ennen kuin sillä voidaan mitata isoja näyte-eriä. 
Yhteenvetona voidaan todeta, että yhdistämällä eri biomerkkiaineita on mahdollista 
parantaa eturauhassyövän riskin ennustamista. Näin vältetään turhien koepalojen ottamista 





Every year thousands of men hear that they have prostate cancer, the most common cancer 
of men in Finland. It causes mental and physical suffering to these men and their families 
as well as significant costs to the healthcare system. In 2010 a total of 4719 men were 
diagnosed with prostate cancer in Finland which was 31.6% of all cancers diagnosed in 
men. Prostate cancer was the second most common cause of cancer deaths among men 
with 847 cases (13.8% of all cancer deaths) after the lung cancer, the cause of death in 
1547 cases (25.2% of all cancer deaths). (Finnish Cancer Registry, 2012) 
Prostate cancer is a slow growing disease and it rarely causes clinical symptoms. Many 
men die without ever knowing they had developed the cancer and most likely the actual 
cause of death is other than prostate cancer. The current question is which cases of 
prostate cancer should we find and treat and which ones do not cause any actual harm to 
the men. The following question is how should we proceed to find those cases of cancer: 
by carrying out age-group specific screening of the entire male population, by estimating 
the risk of each man with some kind of a statistical method or just by reacting to the 
symptoms once they occur? 
Prostate-specific antigen (KLK3, PSA) has had an important role in finding cases of 
prostate cancer since the late 1980s. Large screening studies were started in the 1990s to 
find out how good PSA would be as a screening method and now that the first results have 
been reported the question still remains without an unambiguous answer (Andriole et al., 
2009; Schroder et al., 2009). On one hand, it has become clear over the years that many 
men are diagnosed and also treated unnecessarily because many cases of indolent cancer 
are found by using PSA testing. On the other, there are definitely aggressive cases of 
cancer which need to be found as early as possible to treat the men, increase their life span 
and quality of life and finally prevent the cancer deaths.  
In this thesis, PSA and its different forms in blood circulation as well as human kallikrein-
related peptidase 2 (KLK2, hK2) were studied as possible biomarkers to improve the 
prostate cancer diagnostics. The two proteins are part of a family of 15 proteins for which 
a new nomenclature system was suggested in 2006 (Lundwall et al., 2006). In this system 
the genes encoding each member of the family are called as kallikrein-related peptidases 
(KLK) followed by the number of the gene symbol, except for the first member which is 
still called kallikrein 1. The corresponding proteins are called with the same names except 
that the abbreviations are written in standard font to separate them from the genes which 
are written in italics. Despite the suggestion for nomenclature the old names for KLK3 
and KLK2 are commonly used and for practical reasons in this thesis the old abbreviations 
PSA and hK2 are used instead of the suggested ones. 
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2 REVIEW OF THE LITERATURE 
2.1 Prostate cancer 
Prostate is a male secretory gland situated below the bladder and surrounding the urethra. 
Its biological function is to produce 20% of the liquid that forms the major part of semen. 
It consists of glandular structures which are surrounded by stromal structures. There are 
three distinct parts of the prostate: central, transition and peripheral zones. 
2.1.1 Pathogenesis 
Prostate cancer is both a biologically and clinically heterogeneous disease but it is often a 
slow growing type of cancer and many men have it without any symptoms during their 
life. It has been estimated that 30% of the men over 50 years and 70–80% of the men over 
80 years of age have the cancer but only one out of ten of these cases of latent cancer 
develop into a clinically diagnosed cancer (Jemal et al., 2005; Prostate Cancer: Current 
Care guideline, 2007). The highest rates of prostate cancer occur in the United States and 
Europe while the men in Asia suffer least of the prostate cancer (Hsing et al., 2000). 
Most cases of cancer (70%) occur in the peripheral zone of the prostate and they are 
adenocarcinomas which means that the cancer cells originate from the epithelium (Lee et 
al., 2011). In the normal prostate's glandular structure the epithelial secretory cells are 
columnar, usually as a single-cell high layer, and form acini (round sacs or cavities 
surrounded by the cells) which have a basal cell layer to support the structure. The 
histological definition of prostate cancer involves the loss of the basal cell layer. Prostatic 
intraepithelial neoplasia (PIN) is considered as a premalignant transformation of the 
epithelial cells. The low grade PIN (LGPIN) may have more than one layer of epithelial 
cells but the basal cell layer is still intact. In high grade PIN (HGPIN) the basal cell layer 
is defined as discontinuous and these cells may be difficult to separate from actual well 
differentiated cancer cells. (Ayala and Ro, 2007)  
In its early phases prostate cancer tumor occurs within the prostate capsule and it may be 
multifocal meaning that there are several separated tumors which may even be genetically 
different. If the prostate cancer grows outside of the prostate capsule it may spread to the 
seminal vesicles or bladder neck. If the cancer metastasizes further it may do so either via 
lymph or blood typically to bone.  Both prostate and cancer cells are androgen regulated 
but often, in the late, metastasized phases of the cancer progression, cancer cells lose their 
sensitivity to androgens. 
It seems that environmental factors may have a stronger effect on prostate cancer 
development than inherited factors (Lichtenstein et al., 2002; Lichtenstein et al., 2000). 
About 2–3% of prostate cancers are inherited and approximately 20% appear within 
certain families (Prostate Cancer: Current Care guideline, 2007). Especially a diet with 
increased fat and red meat consumption seems to be related to an increased risk of prostate 
cancer (Giovannucci et al., 1993; Whittemore et al., 1995). On the other hand a diet with a 
high intake of tomatoes (or lycopene from other sources) or soy may protect from the 
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prostate cancer (Badger et al., 2005; Chen et al., 2001; Etminan et al., 2004; Gann et al., 
1999). The effect of diet and environmental factors is probably the key factors in the rise 
of the prostate cancer risk when men from Asia or other low-risk countries move to North 
America (Marks et al., 2004; Shimizu et al., 1991; Watanabe et al., 2000). 
2.1.2   Diagnosis, staging and grading 
Diagnosis 
Prostate cancer may not cause any symptoms in the early phase but after progressing to 
some extent the symptoms may include urinating difficulties, blood secretion in urine or 
bone pain in the cases of already metastasized cancer. When prostate cancer is suspected 
the clinical examination involves serum PSA measurement (in Finland both total and free 
PSA), palpation through rectum which is called digital rectal examination (DRE), and 
later also transrectal ultrasound (TRUS) can be used. Diagnosis is always made by 
histological findings from a prostate biopsy tissue sample. The biopsies (6–12 or even up 
to 21) are taken with a needle under TRUS guidance through rectum (Chun et al., 2010; 
Prostate Cancer: Current Care guideline, 2007). Prostate cancer may also be found 
incidentally in prostate tissue removed during transurethral resection of the prostate 
performed to relieve the symptoms of benign growth of the prostate.  
Prostate cancer symptoms may be similar to symptoms of other diseases of prostate so an 
essential part of prostate cancer diagnosis is discrimination of benign conditions from 
cancer. Most common benign diseases are benign prostatic hyperplasia (BPH) and 
prostatitis. 
In BPH the transition zone of the prostate has grown so much that it causes symptoms, 
most often urinating difficulties. This is caused by the overgrown prostate tissue which is 
squeezing the urethra. The prostate continues to grow throughout a man's life so BPH is 
very common. It has been estimated that approximately 80% of the men over 60 years of 
age have histological signs of BPH and 40% suffer from the symptoms (Garraway et al., 
1991; Sagnier et al., 1996; Sanda et al., 1997). BPH may also cause the serum PSA to 
rise. 
Prostatitis may be caused by a bacterial infection either as an acute or chronic condition. 
Coliform, enterococci and staphylococci bacteria are common causes and the infection can 
usually be cured with antibiotics (Sharp et al., 2010). Infectious prostatitis may occur after 
taking a prostate biopsy (Loeb et al., 2011; Nam et al., 2010).  It is also possible that 
prostatitis is caused by inflammation without any signs of bacterial infection. The disease 
is called chronic pelvic pain syndrome, and its etiology is not known. This syndrome can 
also exist without inflammatory signs and it may also cause the serum PSA to rise. Some 
prostatitis cases are found only in histological samples taken due to some other urological 
conditions. (Sharp et al., 2010.) 
Prostate cancer fulfills many characteristics of a disease which could be screened across 
the male population. It is a major health issue, there is a screening method with which it 
can be found in an early stage and it is curable at its early stage. The most common 
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screening method is the PSA measurement, but also DRE or TRUS can be used for 
screening. The screening of prostate cancer seems to lead to some reduction in mortality 
with the cost of over-detection and overtreatment (Schroder et al., 2009; Schroder et al., 
2012). Over-detection means that many cases of cancer that would not cause any harm to 
the men are detected and thus many unnecessary biopsies are taken causing unnecessary 
anxiety to the men. Over-detection may lead to overtreatment which means that cases of 
cancer that could be followed without treatment are actually treated with aggressive 
methods which may cause more serious side-effects than just doing nothing. In addition to 
this, there is no information on the cost-benefit ratio of the screening or how screening 
affects the quality of life. Thus, the population-based screening is not currently 
recommended in Finland (Prostate Cancer: Current Care guideline, 2007). The effect of 
PSA-based screening is discussed in more detail in chapter 2.2.2. 
Stage 
The extent, or spread, of the prostate cancer is defined by the TNM staging classification 
of American Joint Committee on Cancer and the International Union against Cancer 
(Table 1). The classification system is based on the cancer status of the prostate gland 
itself (T), lymph nodes (N) and other metastases (M). Organ-confined cancers are not 
growing outside of the prostate capsule and non-organ-confined cancers have grown 
through the capsule. Pelvic lymph nodes are usually the first lymph nodes where the 
prostate cancer metastasizes and the very advanced cancer most often send metastases to 
the bones. 
The histopathological staging of the prostate can be done after removal of the prostate 
(radical prostatectomy). Essentially the same definitions are used for both clinical (cTNM, 
Table 1) and pathological (pTNM) staging. The pathological staging may provide some 
additional information, for example whether there is a possibility that some extracapsular 
parts of the tumor have not been successfully removed. 
Grade 
Prostate cancer's progression can be estimated by grading the histological tissue sample. 
The grading classifies the tissue patterns by the morphology of the tissue structures or the 
cell morphology. Usually, the more differentiated the cells and other structures are the less 
aggressive the cancer is. The loss of glandular structure and deformed cells are usually a 
sign of potentially aggressive cancer which may end up sending metastases to other parts 
of the body. 
Gleason grading is a commonly used method to evaluate prostate cancer tissue. It was 
developed by Dr. Donald Gleason with The Veterans Administration Cooperative 
Research Group in 1966 (Gleason, 1966; Gleason and Mellinger, 1974). It has been 
updated since the first publication and the latest version was published in 2005 (Epstein, 
2010; Epstein et al., 2005). The Gleason grading system is based on the overall 
appearance of the tissue and the individual cell morphology does not play an important 
role. It takes into account that the cancer cells do not progress uniformly and that there 
may be several different types of cancer tissue in one prostate. The Gleason grade is given 
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in numbers between 1 and 5 so that the most differentiated tissue is given grade 1 and the 
least differentiated tissue is grade 5 (see Figure 1). The two predominant patterns, 
primary and secondary, are graded, and the grades are then added up to get the Gleason 
score which can vary between 2 and 10. 
Table 1. The 1997 TNM cancer staging classification of the American Joint Committee 
on Cancer and the International Union against Cancer for prostate cancer. TNM stands for 
Tumor, Nodes, Metastases. The classification system was updated in 2002 and 2009 but 
the 1997 version is shown here because it was used in the current study (Edge et al., 2010; 







TX  Primary tumor cannot be assessed 
T0  No evidence of primary tumor 
T1  Clinically inapparent tumor, not palpable or visible by imaging 
 T1a Incidental histologic finding in < 5% of resected tissue 
 T1b Incidental histologic finding in > 5% of resected tissue 
 T1c Tumor identified by needle biopsy (e.g. due to elevated PSA) 
T2  Confined within the prostate 
 T2a Tumor involves one lobe 
 T2b Tumor involves both lobes 
T3  Tumor extends through the prostate capsule but has not spread to other organs 
 T3a Extracapsular extension (unilateral or bilateral) 
 T3b Tumor invades seminal vesicles 
T4 
 
Tumor is fixed or invades adjacent structures other than seminal 
vesicles: bladder neck, external sphincter, rectum, levator 







NX  Regional lymph nodes cannot be assessed 
N0  No regional lymph node metastasis 







MX  Distant metastasis cannot be assessed 
M0  No distant metastasis 
M1  Distant metastasis 
 M1a Non-regional lymph node metastasis 
 M1b Bone metastasis 
 M1c Metastasis at other sites 
 




Figure 1. The Gleason grading of prostate cancer (Modified from Epstein et al., 2005 by 
Johanna Vuojola). 
 
Another type of grading has been named as World Health Organization (WHO) grade 
which was developed by Dr. F. K. Mostofi in 1975 (Mostofi, 1975). In this grading system 
the cell morphology is also taken into account. The evaluated characteristics include 
increased cellularity, nuclear crowding, disturbance of cellular polarity, failure of 
differentiation of epithelial cells from the basal layer of epithelium, polymorphism, 
irregularity in cell size, variations of shape and chromatin pattern of the nuclei, displaced 
or abnormal mitotic figures and giant cells. The grading is given in numbers from 1 to 3 in 
which the grade 1 is the least anaplastic (i.e. the cells are more differentiated) and the 
grade 3 is the most anaplastic type (i.e. the cells are not differentiated). 
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2.1.3 Treatment and prognosis 
The treatment of prostate cancer is currently efficient for localized cancer, especially for 
organ-confined tumors. The low stage, low grade cancers can be left without treatment 
under so called watchful waiting or active surveillance, especially if the patient is over 70 
years old (or the expected lifetime is less than 10 years for other reasons than prostate 
cancer). The localized cancers are most often treated with removal of the prostate (radical 
prostatectomy) or with different forms of radiation therapy. The prognosis is good, the  
10-year survival rate is 90–94% (Albertsen et al., 2007; Lu-Yao and Yao, 1997). 
The treatment may have adverse effects like complications during the surgery and post-
treatment incontinence or impotency. The rates for retaining continence and potency vary 
between different treatment techniques and for example between different surgeons. 
Generally 58–97% of the radical prostatectomy patients retain continence and 31–94% 
retain potency. The overall complication rate during radical prostatectomy operations is 
approximately 10%. (Coelho et al., 2010.) Radiation therapy may also cause side effects 
to a significant number of patients (up to 20 %) (Prostate Cancer: Current Care guideline, 
2007). Due to these possible adverse effects treatment of an indolent cancer may cause 
more harm than benefit to the patient. 
If the cancer has metastasized, it may be treated with both radical prostatectomy or 
radiation therapy and castration by removal of testes (orchiectomy) or chemically 
preventing androgen secretion. As the prostate cells are under androgen regulation this 
kind of treatment may prolong the patient's life by 2–3 years but if the cancer turns into a 
hormone-resistant type the lifetime expectancy is only from half to one and half years 
(Berry et al., 2006; Tannock et al., 1996). 
2.2 Free prostate-specific antigen forms in prostate cancer 
diagnostics 
2.2.1 Structure and function of prostate-specific antigen (PSA) 
PSA (KLK3) is a serine protease produced in the prostate epithelial cells as a 261 amino 
acid preproPSA. The 17 amino acid prepeptide is cleaved in endoplasmic reticulum and 
the resulting proPSA is transported to the plasma membrane (McCormack et al., 1995). 
The 7 amino acid propeptide is cleaved to produce the enzymatically active PSA which 
has chymotrypsin-like substrate specificity. PSA is secreted to the lumen of prostatic ducts 
and eventually it forms part of the seminal fluid. PSA is activated by hK2 (KLK2), KLK4, 
trypsin and other kallikreins (Kumar et al., 1997; Lovgren et al., 1997; Takayama et al., 
2001a; Takayama et al., 1997; Takayama et al., 2001b; Yoon et al., 2007) and its main 
biological function is to cleave gel-forming proteins in semen to liquefy the semen and 
thus enable spermatozoa motility (Lilja, 1985; Lilja et al., 1987; Malm et al., 2000; 
McGee and Herr, 1988). PSA has also many putative functions which relate to, for 
example, enhancing the invasion and proliferation of tumor cells (Lawrence et al., 2010). 
The five disulfide bonds hold the molecule together even if it would be inactivated 
through internal peptide bond cleavages. 
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The molecular mass of PSA polypeptide is 26 079 Da. PSA has one glycosylation site at 
Asn45 and the carbohydrate moiety increases the mass with approximately 2300 Da. 
Therefore,  depending on the structure of the moiety, the overall mass of PSA is around  
28 400 Da (Belanger et al., 1995; Mattsson et al., 2008). PSA protease function is partly 
regulated by complex formation with its inhibitors of which α1-antichymotrypsin (ACT, 
SERPINA3) and α2-macroglobulin (A2M), α1-antitrypsin (AT or API, SERPINA1) and 
protein C inhibitor (PCI, SERPINA5) are the most important (Christensson et al., 1990; 
Christensson and Lilja, 1994; Espana et al., 1991; Stenman et al., 1991; Zhang et al., 
1997). Most of the PSA in the prostate tissue and seminal plasma is in free and active 
(noncomplexed) form (Christensson and Lilja, 1994; Denmeade et al., 1997; Espana et al., 
1993; Mikolajczyk et al., 1997a; Mikolajczyk et al., 2000b). The PSA found in blood 
circulation is mostly (65–95%) complexed but the inactive forms (5–35%), including 
proPSA and internally cleaved forms, do not form complexes (Lilja et al., 1991; Stenman 
et al., 1991; Zhang et al., 1999). 
PSA is almost exclusively expressed in the prostate even though it has been detected in 
small quantities in other tissues and body fluids (Shaw and Diamandis, 2007). The 
epithelial cells secreting PSA have a strong polarity towards the prostatic ducts and only a 
very small proportion of the PSA is able to escape into blood circulation. The structural 
changes in tissue caused by different disease states cause more PSA to enter the blood 
stream which is the rationale for using PSA as a biomarker. As infections, inflammations 
and benign growth (BPH) of the prostate can cause more PSA to escape into the blood as 
well, PSA is not a prostate cancer specific marker but rather an indicator of an abnormal 
prostate status. 
2.2.2 Circulating PSA as a marker for prostate cancer 
Since the first proposal of using PSA for cancer detection (Papsidero et al., 1980) it has 
become the most important tumor marker – despite its lack of specificity. The ways of 
using PSA measurements differ greatly between different countries. In the United States 
and Canada the PSA measurements are very common and they are recommended by 
different organizations but in slightly different way (Greene et al., 2009; Heidenreich et 
al., 2011; Kawachi et al., 2010; Wolf et al., 2010). The general trend seems to encourage 
the patient and doctor to discuss all possible consequences of performing the assay and 
then base the decision on the discussion. As new information emerges from the studies the 
recommendations have been changing since the widely accepted suggestion to use  
4 ng/mL PSA cut-off for further examination by Catalona et al. (Catalona et al., 1991).  
Recently, two large population-based randomized prostate cancer screening studies have 
reported results which were somewhat controversial. The North American Prostate, Lung, 
Colorectal, and Ovarian (PLCO) Cancer Screening Trial reported that PSA-based 
screening did not affect prostate cancer mortality after a 7 to 10 year follow-up (Andriole 
et al., 2009) while the European Randomized study of Screening for Prostate Cancer 
(ERSPC) reported a 20–30% reduction in prostate cancer deaths but also a need for large 
number of men screened (> 1000 men) and diagnosed (37 men) with cancer to prevent one 
prostate cancer death (Roobol et al., 2009b; Schroder et al., 2009; Schroder et al., 2012). 
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In other words, there is a big risk for over-detection (overdiagnosis) which may lead to 
overtreatment: while only a part of the diagnosed cases of cancer are actually life 
threatening it may be difficult to predict which cases are indolent and which need to be 
treated. Furthermore, many men do not want to live with the cancer and want to be treated 
rather than rely on active surveillance of the cancer. In addition to causing costs to the 
healthcare system, the side-effects of an unnecessary treatment (for example urinary 
problems or impotence after removal of the prostate) may turn out to be worse than doing 
nothing. Another side of the procedure is the false-positive rate in the screening. In 
Finland, approximately 7% of the screened men had a PSA value above the screening cut-
off but no cancer was found in the following biopsy, and when attending several rounds of 
screening as many as one in every eight men may have a false-positive result (Kilpelainen 
et al., 2010). This emphasizes the need for better tools for estimating the cancer risk of an 
individual man.  
In Europe PSA is used less than in the North America and it is recommended in many 
countries only for symptomatic patients. The degree of so called opportunistic screening 
for prostate cancer differs between countries as well. Opportunistic screening means that 
patients or clinicians want to measure PSA values even though there may not be any direct 
evidence for the need for it.  
In Finland, The Current Care guideline suggests PSA measurements only for symptomatic 
patients (Prostate Cancer: Current Care guideline, 2007). Total PSA (tPSA) 
concentrations, comprising both complexed and free PSA forms, rise with age and, 
therefore, age-specific reference ranges are used (Table 2). For patients with tPSA values 
within the range of 2.5–10 ng/mL the measurement of the free PSA (fPSA) is 
recommended because the ratio of fPSA and tPSA (F/T PSA) is generally lower in 
prostate cancer patients and calculating the F/T PSA ratio is likely to help in deciding 
whether a biopsy is necessary (Table 3). In addition to using tPSA as an aid in cancer 
diagnostics it is widely used for the follow-up of the radical prostatectomy patients. The 
PSA concentration in their blood circulation should remain low and a rising concentration 
is usually a sign of a recurrent cancer.  
Table 2. Age-specific reference ranges for total PSA (tPSA) used in Finland. µg/L = 
ng/mL (Catalona et al., 1994; Prostate Cancer: Current Care guideline, 2007; Thompson 
et al., 2004) 
Age (years) Serum tPSA (µg/L) 
40–49 < 2.5 
50–59 < 3.5 
60–69 < 4.5 
70–79 < 6.5 
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Table 3. PSA concentrations and prostate cancer risk. µg/L = ng/mL (Catalona et al., 
1994; Prostate Cancer: Current Care guideline, 2007; Thompson et al., 2004) 
PSA concentration in 
serum or plasma Risk of prostate cancer 
  




> 10 > 50 
  
F/T PSA (%) when 





> 25 8 
 
F/T PSA has been shown to help in discriminating prostate cancer from BPH in many 
studies since the first publications of serum fPSA (Lilja et al., 1991; Stenman et al., 1991). 
The F/T PSA has helped in discriminating men with and without cancer with a tPSA 
within the range of 2.5–10 ng/mL but it seems that the discriminative power is decreased 
in men with a tPSA of 2.5–4 ng/mL (Bangma et al., 1997; Catalona et al., 1998; 
Raaijmakers et al., 2004; Recker et al., 2001). However, an F/T PSA < 15% in men with a 
tPSA < 3 ng/mL may predict future cancer (Finne et al., 2008). In addition, F/T PSA 
seems to help in predicting cancer aggressiveness (Bjork et al., 1999; Raaijmakers et al., 
2004; Shariat et al., 2006; Southwick et al., 1999). fPSA is also a significant factor, 
together with tPSA, in many statistical models predicting prostate cancer risk (Chun et al., 
2007; Finne et al., 2004; Steuber et al., 2007a; Vickers et al., 2008). The models and risk 
calculators are discussed in more detail in chapter 2.5.   
In addition to F/T PSA ratio, PSA velocity and density have also been suggested to help in 
assessing the prostate cancer risk. PSA velocity (PSAV) is calculated from PSA 
measurements made over a period of time to see whether the PSA concentration is rising, 
which can be a sign of developing disease (BPH or prostate cancer) (Carter et al., 1992; 
Loeb et al., 2007; Meeks et al., 2008). According to the Finnish Current Care guideline 
further examination is recommended when a PSAV exceeds 0.75 ng/mL per year (based 
on three measurements made within a time period of at least one year) in a man with tPSA 
within the range of 4–10 ng/mL. However, PSAV may not exceed the significance of F/T 
PSA in a screening setting as has been suggested recently (Schroder et al., 2006; Ulmert et 
al., 2008; Vickers et al., 2009). 
PSA density (PSAD) is the serum (total) PSA concentration divided by the prostate 
volume. As prostate volume, as well as serum PSA, increases with age and in BPH it has 
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been suggested that large amounts of PSA leaking into blood circulation from a small 
prostate, thus increasing the ratio of PSAD, would be an indication of cancer (Epstein et 
al., 1994; Freedland et al., 2005; Kranse et al., 1999; Roehrborn et al., 1999a; Roehrborn 
et al., 1999b; Seaman et al., 1993). Prostate volume and PSAD have provided additional 
discriminative power in some statistical models predicting cancer risk or cancer pathology 
(Newton et al., 2010; Radwan et al., 2007; Roobol et al., 2012). More aggressive types of 
cancer have been found in small prostates but there is debate about whether this is caused 
by the biology of the cancer or whether it is due only to PSA measurement or biopsy 
regime characteristics (Briganti et al., 2007; Newton et al., 2010; Ngo et al., 2012; van 
Leeuwen et al., 2009). However, the volume measurement (or estimation) requires either a 
digital rectal examination (Roobol et al., 2012) or transrectal ultrasound measurement 
which should be performed by a urologist and are considered to be invasive procedures. 
The current commercial immunoassays for tPSA measure free and complexed forms 
(mostly PSA-ACT) but not PSA bound to A2M which is not immunoreactive in 
conventional immunoassays. The assays are expected to recognize both forms equally 
(equimolar recognition) and the manufacturers should inform the users on how the assays 
are calibrated. The equimolarity and standardization issues are discussed in more detail in 
chapter 2.4.2. A few assays for measuring complexed PSA (cPSA) exist but it seems that 
its clinical significance is approximately the same as that of fPSA measurement (Leinonen 
et al., 1993). Most manufacturers offer fPSA assays which are generally expected to 
recognize all noncomplexed PSA forms. There are also immunoassays which are specific 
for certain subforms of fPSA. 
The first studies investigating the different forms of free PSA in serum were made in the 
mid-1990s. Huber et al. (1995) found that the pI values of PSA forms in the serum of 
prostate cancer patients were higher than in the serum of BPH patients and they speculated 
that different glycosylation would explain this difference (Huber et al., 1995). A few years 
later the precursor forms, or proPSA, as well as internally cleaved forms were found in the 
serum of prostate cancer patients (Mikolajczyk et al., 1997a; Noldus et al., 1997). Soon it 
was reported that the proPSA and inactive intact mature forms were more abundant in the 
serum of prostate cancer patients while the serum of BPH patients had more internally 
cleaved forms (Charrier et al., 1999; Hilz et al., 1999; Qian et al., 1997). These findings 
were supported by observations of different PSA forms in prostate tissue. Internally 
cleaved, or nicked, PSA was found in BPH nodules and proPSA forms were more often 
present in cancer tissue than in benign transition zone tissue (Chen et al., 1997; 
Mikolajczyk et al., 2000a). The different fPSA forms and their clinical use are described 
in more detail in the Figure 2 and in the following chapters. 




Figure 2. fPSA subforms and the immunoassays recognizing them. PSA is presented as 
the bar in which the propeptide is gray, propeptide cleavage sites are marked with dashed 
vertical lines and internal cleavage sites with solid vertical lines. The amino acids at 
internal cleavage sites are indicated. The forms detected by different immunoassays are 
indicated on the left (fPSA-I and fPSA-N) and on the right (proPSA and BPSA).  
2.2.3 Precursor forms of PSA (proPSA) 
The pro-sequence of PSA consists of seven N-terminal amino acids which are cleaved by 
hK2, trypsin or other proteases to form the enzymatically active mature PSA. The process 
is very rapid and efficient as no proPSA have been found in seminal plasma (Mikolajczyk 
et al., 2001). In the prostate tissue and in the serum of prostate cancer patients PSA forms 
with different number of pro-sequence amino acids have been found. The number of the 
remaining amino acids is depicted by a negative number: [-7] referring to the full length 
pro-sequence and [-1] for the last amino acid before the mature PSA sequence starts. Most 
common proPSA forms are [-7], [-5], [-4] and [-2] while the forms [-6] and [-3] have not 
been found (Peter et al., 2001). All proPSA forms are inactive but the [-5] and [-4] 
proPSA forms can be activated with hK2 or trypsin while the [-2]proPSA cannot 
(Mikolajczyk et al., 2001). This probably enhances [-2]proPSA stability both in the 
prostate tissue and in the blood circulation making it a potential marker for prostate cancer 
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Immunoassays recognizing different proPSA forms have been developed. An assay that 
measures [-7] and [-5] forms simultaneously, i.e. [-5,-7]proPSA assay, as well as assays 
for [-4] and [-2]proPSA forms have been developed by Hybritech Inc. (San Diego, USA), 
a Beckman Coulter subsidiary (Khan et al., 2003; Mikolajczyk et al., 2004; Mikolajczyk 
et al., 2001; Sokoll et al., 2003; Sokoll et al., 2008). The assays have minimal cross-
reactivity with other proPSA forms. Another assay for [-5,-7]proPSA was developed by 
Humboldt University (Berlin, Germany) in collaboration with Roche Diagnostics 
(Penzberg, Germany) (Bangma et al., 2004; Hösel et al., 2002; Lein et al., 2005).  
Several studies investigating the clinical potential of different proPSA forms have been 
conducted. Most of them have been rather small-scale and preliminary in nature (Bangma 
et al., 2004; de Vries et al., 2005; Khan et al., 2003; Khan et al., 2004; Mikolajczyk et al., 
2004; Naya et al., 2004; Naya et al., 2005; Sokoll et al., 2003; Sokoll et al., 2008). In a 
larger study (n = 1091) Catalona et al. found that using the ratio of summed 
concentrations of proPSA forms to fPSA concentration (%pPSA) improved the specificity 
of cancer detection over F/T PSA in men with a tPSA range of 2–10 ng/mL and that 
higher [-2]proPSA/fPSA ratios were associated with more aggressive cancer in cancer 
patients (Catalona et al., 2003; Catalona et al., 2004).  
The results from studies measuring the [-5,-7]proPSA in cancer patients have not showed 
that this form would have clinical significance over F/T PSA (Bangma et al., 2004; 
Catalona et al., 2003; Lein et al., 2005; Stephan et al., 2006c) despite some contradictory 
data (Miyakubo et al., 2009; Stephan et al., 2007). Therefore, the recent studies have 
concentrated on the clinical utility of [-2]proPSA. 
A common observation in most of the studies is that none of the proPSA forms is 
clinically useful as a single marker but rather in combination with either fPSA or tPSA (or 
both). The median concentration of [-2]proPSA in  serum is approximately 14 pg/mL 
ranging from 1 pg/mL to nearly 100 pg/mL. The [-2]proPSA/fPSA ratio is approximately 
1.5% ranging from under 0.5% to 6% and the ratio tends to be higher in cancer patients 
than in men without cancer (Guazzoni et al., 2011; Sokoll et al., 2010). Recently, more 
evidence of the true clinical value of [-2]proPSA has accumulated after the launch of the 
automated p2PSA immunoassay by Beckman Coulter. The studies consistently show that 
[-2]proPSA has additional value in predicting prostate cancer risk at initial biopsy and it 
could help in reducing unnecessary biopsies either as a ratio to fPSA or in a mathematical 
formula called "Beckman Coulter prostate health index" or phi. In the formula the 
concentration of [-2]proPSA has been combined with fPSA and tPSA concentrations. The 
phi is discussed in more detail in chapter 2.5.1. (Catalona et al., 2011; Guazzoni et al., 
2012; Guazzoni et al., 2011; Isharwal et al., 2011; Jansen et al., 2010; Le et al., 2010; 
Sokoll et al., 2010; Stephan et al., 2009b) 
More controversial data has been reported regarding the value of [-2]proPSA in predicting 
the aggressiveness of the prostate cancer. For example, Sokoll et al. reported  
[-2]proPSA/fPSA to be related with cancer aggressiveness in 245 prostate cancer patients 
(Sokoll et al., 2010) but Jansen et al. state that it has limited additional value in 
identifying aggressive prostate cancer in 756 studied men of whom 400 were cancer cases 
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(Jansen et al., 2010). Catalona et al. and Guazzoni et al. have reported the ability of either 
phi or [-2]proPSA/fPSA to predict high-grade cancer (Catalona et al., 2011; Guazzoni et 
al., 2012) even though Guazzoni et al. were more cautious in their conclusions regarding 
the relationship. In their earlier study of 268 men they found [-2]proPSA/fPSA to correlate 
with Gleason score but unable to improve the prediction of Gleason score of the prostate 
cancer in the biopsy (Guazzoni et al., 2011). In the artificial neural network model created 
by Stephan et al. the inclusion of [-2]proPSA into the model improved prostate cancer 
detection and could replace prostate volume and DRE information in it (Stephan et al., 
2009b). Similar results were reported by Guazzoni et al. (2011) who reported the 
predictive accuracy of [-2]proPSA/fPSA and phi to exceed, for example, that of PSA 
density (see chapter 2.2.2).  
2.2.4 Intact free PSA (fPSA-I) 
The intact free PSA, or fPSA-I, is a PSA form which does not have an internal cleavage at 
the Lys145/Lys146 (Nurmikko et al., 2000). The fPSA-I immunoassay is based on a 
unique antibody 4D4 (or 5C3) which does not recognize the PSA with cleavage at this 
site. The cleavage may also occur at Lys146/Leu147 (Chen et al., 1997; Vegvari et al., 
2012) which is not recognized by the 4D4 either. For simplicity, in this thesis the site 
Lys145/Lys146 is used to refer to both possible sites. The cleavage at Lys145/Lys146 is 
probably the most common nicking site with or without other cleavages at Arg85/Phe86 
or Lys182/Ser183 (Christensson et al., 1990; Linton et al., 2003; Mattsson et al., 2008; 
Noldus et al., 1997). The immunoassay recognizes both proPSA and mature PSA which 
may be in either inactive (Christensson et al., 1990; Zhang et al., 1995) or active form. 
Active PSA is found in very low amounts (~3% of fPSA) in the circulation (Niemelä et 
al., 2002). As it is possible that, for example, cleavage at Lys182/Ser183 exists without a 
cleavage at Lys145/Lys146 (Linton et al., 2003) the fPSA-I fraction is not fully intact 
PSA (i.e. PSA without any internal cleavages) but it is not clear whether the proportion of 
PSA with nicks somewhere else but not at Lys145/Lys146 is clinically significant. In 
seminal plasma the proportion of PSA with cleavage at Lys182/Ser183 but without one at 
Lys145/Lys146 is estimated to be approximately 10% so the proportion of it in blood 
circulation is likely to remain below or rise to 10% at the most (Linton et al., 2003). 
The first clinical studies assessing the value of fPSA-I suggested that the fPSA-I/fPSA 
ratio (I/F PSA) would help in discriminating men with and without cancer or benign 
disease (Niemelä et al., 2002; Nurmikko et al., 2001). The average serum fPSAI 
concentration is generally between 0.4 and 0.6 ng/mL and the short-term intra-individual 
variation of fPSA-I seems to be rather small (Christensson et al., 2011). The change in the 
fPSA-I concentrations over a longer time period, i.e. fPSA-I velocity, is unlikely to 
facilitate predicting prostate cancer in biopsy (Vickers et al., 2009).  
The fPSA-I concentration as a single marker has not been significant in predicting the 
presence of prostate cancer. fPSA-I amounts to approximately 40–60% of fPSA and its 
ratio to fPSA is generally higher in cancer patients than in men without cancer (Gupta et 
al., 2010; Niemelä et al., 2002; Nurmikko et al., 2001; Vickers et al., 2010a; Vickers et 
al., 2008). In a study of Steuber et al. (2005) fPSA-I concentration was not predictive of 
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prostate volume but it seemed to be associated with cancer volume despite the lack of 
statistical significance (Steuber et al., 2005).  
Later studies involved examination of large screening cohorts participating the European 
Randomized study of Screening for Prostate Cancer (ERSPC). Based on 740 screened 
men with elevated tPSA in Gothenburg, Sweden, a statistical model including fPSA-I as 
well as age, tPSA, fPSA and hK2 was developed for predicting the outcome of the initial 
biopsy. The model was able to significantly reduce the number of unnecessary biopsies, 
the reduction being 57% if a 20% risk of cancer would have been used as an indication for 
biopsy (Vickers et al., 2008). Later studies confirmed these results in the previously 
unscreened men (Vickers et al., 2010a) but also in recently screened men (Vickers et al., 
2010b; Vickers et al., 2010c). fPSA-I is an essential part of the panel as demonstrated by 
the decrease in the predictive accuracy when fPSA-I is removed (Vickers et al., 2011). 
The kallikrein panel is described and discussed in more detail in chapter 2.5.1.  
2.2.5 Nicked free PSA (fPSA-N) 
Nicked free PSA is defined as the fraction of free PSA containing the internal cleavage at 
Lys145/Lys146, thus being the fraction which is unrecognizable by the antibody 4D4 (or 
5C3). As discussed in the previous chapter regarding fPSA-I (2.2.4) this cleavage may be 
the only one but it may also exist together with other internal cleavages. In various studies 
the fPSA-N concentrations have been calculated by subtracting fPSA-I concentrations 
from fPSA concentrations because there has not been a direct fPSA-N immunoassay 
available. A prototype of a direct fPSA-N assay was developed by Pauliina Niemelä in her 
doctoral thesis (Niemelä, 2002) and the assay was further optimized and published (IV) 
during this study. 
BPH nodules and hyperplastic tissue in general contain more internally cleaved forms of 
PSA than proPSA forms or mature inactive PSA (Chen et al., 1997; Mikolajczyk et al., 
2000b). The biological reason for this is currently unknown but it is thought that PSA is 
exposed to different proteases in the prostate tissue before diffusion to blood circulation. 
The clinical value of fPSA-N seems to be in discriminating BPH patients from prostate 
cancer patients. Especially, the ratio of fPSA-N to tPSA (N/T PSA) has been significant in 
predicting the presence of benign enlargement of the prostate (Niemelä et al., 2002; 
Nurmikko et al., 2001; Steuber et al., 2002). Ever since the first studies it has seemed 
evident that fPSA-N values as such are not of clinical value for individual patients but in a 
statistical combination with tPSA and fPSA the value might be much greater (Steuber et 
al., 2005; Steuber et al., 2002). As fPSA-N concentrations have been calculated from 
fPSA and fPSA-I concentrations either fPSA-N or fPSA-I has usually been excluded from 
the models to avoid problems that might be caused by their strong correlation with each 
other, or multicollinearity. In studies by Steuber et al. (2005 and 2007) fPSA-N was used 
in multivariate models. First, fPSA-N was found to be a significant predictor of prostate 
transition zone volume which is the common site for benign enlargement of the prostate 
(Steuber et al., 2005). In the second study (Steuber et al., 2007a), N/T PSA was found to 
be a strong univariate predictor of initial biopsy outcome, and fPSA-N was chosen into a 
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multivariate model with tPSA, fPSA and different forms of soluble urokinase plasminogen 
activator receptor (suPAR). fPSA-N was not an independent predictor in the model but 
provided additional diagnostic information. Also, it has been shown that the change in the 
fPSA-N concentrations over time, i.e. fPSA-N velocity, is not predictive of prostate cancer 
(Vickers et al., 2009). In the same study, a logistic regression model including age, tPSA 
and fPSA-N had a better diagnostic performance (in terms of AUC, see chapter 2.5.1 for 
explanation) than age and tPSA combined with either fPSA, F/T PSA, fPSA-I or hK2. 
2.2.6 Benign PSA (BPSA) 
Benign PSA (BPSA) has a distinctive internal cleavage at Lys182/Ser183 which occurs 
most often together with a cleavage at Lys145/Lys146 as well as other cleavages.  
A fraction of BPSA (10–30%) may be without the cleavage at Lys145/Lys146 as 
discussed in chapter 2.2.4. BPSA was found in BPH nodules in transition zone of the 
prostate (Mikolajczyk et al., 2000b) and later, after development of an immunoassay, in 
the serum of both BPH and prostate cancer patients comprising, on average, 25% of the 
fPSA fraction (Linton et al., 2003). The Beckman Coulter automated BPSA immunoassay 
is named Access BPHA assay and it is available for research use only (Stephan et al., 
2009a). 
The clinical value of BPSA seems to be much like that of fPSA-N. BPSA has been found 
to correlate with prostate volume (Canto et al., 2004; Naya et al., 2004). Thus, it may be 
more useful in discriminating BPH patients from prostate cancer patients than in a 
screening setting but the results from different studies are somewhat controversial (Jansen 
et al., 2010; Khan et al., 2004; Sokoll et al., 2008; Stephan et al., 2009a). Again, it is 
likely that this form of fPSA is not clinically useful alone but rather used in relation to 
tPSA, fPSA or [-2]proPSA or in combination with them in a statistical model (de Vries et 
al., 2005; Stephan et al., 2009a). The data regarding the ability of BPSA to predict 
aggressive cancers is also contradictory and no definitive conclusions can be made yet  
(de Vries et al., 2005; Jansen et al., 2010; Stephan et al., 2009a). 
2.2.7 Other free PSA forms 
Glycovariants 
The glycosylation patterns of proteins are different in cancer cells than in normal cells and 
this difference could be detected and used in diagnostics (Drake et al., 2010). PSA has one 
N-linked glycosylation site at Asn45 (Belanger et al., 1995) and different glycosylation 
patterns between normal, BPH and prostate cancer have been found (Li et al., 2011; 
Ohyama et al., 2004; Peracaula et al., 2003; Tabares et al., 2007; Tabares et al., 2006; 
White et al., 2009). It seems that in prostate cancer PSA forms contain less sialic acid and 
more fucose than BPH derived PSA (Dwek et al., 2010; Sarrats et al., 2010). The research 
on the clinical significance of different glycovariants of serum fPSA has been rather 
limited and it has been hindered by the technological obstacles due to the requirements for 
sensitivity (high PSA concentrations needed) or demanding technology which is not 
readily available (Dwek et al., 2010). Recently, enzyme-linked lectin assays (ELLAs) 
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have been published (Dwek et al., 2010; Meany et al., 2009), which may ease further 
studies to clarify the clinical significance of different glycovariants. 
Alternatively spliced variants 
Several different alternatively spliced variants of KLK3 gene have been found (David et 
al., 2002; Heuze et al., 1999; Heuze-Vourc'h et al., 2003; Pampalakis et al., 2008; Schulz 
et al., 1988; Tanaka et al., 2000). Many of them have been detected on mRNA level but 
only a few on protein level in prostate tissue or prostate cancer cell lines (David et al., 
2002; Heuze-Vourc'h et al., 2003; Kumar et al., 2000). To date, there are only 
speculations that these protein variants could be present also in blood circulation but 
whether they would have any clinical significance remains to be seen. 
2.3 Kallikrein-related peptidase 2 (hK2) in prostate cancer 
diagnostics 
2.3.1 Structure and function of hK2 
Human kallikrein-related peptidase 2 (KLK2, hK2) shares 79% of its amino acid sequence 
with PSA (Schedlich et al., 1987) as well as many epitopes which are recognized by 
antibodies developed originally against PSA (Piironen et al., 1998). Like PSA, it is 
produced almost exclusively in the prostate and secreted into the prostatic fluid 
(approximately 0.1–2% of PSA concentrations). hK2 has trypsin-like substrate specificity 
and it is thought that hK2 activates proPSA in the semen but it may also cleave 
semenogelins. (Deperthes et al., 1995; Deperthes et al., 1996; Kumar et al., 1997; 
Lovgren et al., 1997; Magklara et al., 2000; Takayama et al., 1997). In seminal plasma 
hK2 forms a complex with PCI (SERPINA5) within ten minutes and this complex is the 
major form found in semen (Deperthes et al., 1996; Grauer et al., 1996; Heeb and Espana, 
1998). In addition, hK2 has most probably an important role in activating other kallikreins 
and proteins in enzyme cascades (Lawrence et al., 2010). 
Unlike PSA, most of the serum hK2 is in free form but some of the hK2 forms complexes 
with ACT (Becker et al., 2000a; Black et al., 1999; Grauer et al., 1998). The complex 
with PCI has not been found in serum (Grauer et al., 1998) and a possible complex with 
A2M would not be detectable by conventional immunoassays. There is a lack of 
information about other complexed hK2 forms in serum. The free hK2 (fhK2) may occur 
in serum as a mature form as hK2 is able to autoactivate (Denmeade et al., 2001; 
Mikolajczyk et al., 1997b). It is also probable that nicked forms of fhK2 are present in the 
blood circulation (Lovgren et al., 1999; Mikolajczyk et al., 1999). Due to the close 
resemblance between hK2 and PSA it is likely that other fhK2 variants similar to fPSA 
variants exist. There may be variation in length of the peptide backbone and in 
glycosylation, splicing or nicking. Despite the majority of the circulating hK2 being in 
free form, the ratio of fhK2 to total hK2 (thK2) seems to vary between 15–100% 
(Vaisanen et al., 2004; Vaisanen et al., 2006).  
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In general, hK2 concentrations in blood are less than 2% of tPSA concentrations which 
requires very sensitive assays for detection of circulating hK2. As the covariation of PSA 
and hK2 in circulation is < 60% and their immunohistochemical expression patterns in 
prostate tissue are different, hK2 is considered to be independent of PSA as a potential 
marker (Charlesworth et al., 1997; Piironen et al., 1996a; Tremblay et al., 1997). 
2.3.2 Total and free hK2 in prostate cancer diagnostics 
It has been found in several studies that hK2 concentrations are elevated in patients with 
prostate disorders. Whether measuring hK2 concentrations is of an independent clinical 
value has been a more controversial issue. There are studies that report hK2 measurement 
being helpful in discriminating prostate cancer patients from non-cancer patients and other 
studies where hK2 has been shown to add information in predicting the cancer stage or 
grade pre-operatively (Becker et al., 2003; Haese et al., 2001; Kwiatkowski et al., 1998; 
Recker et al., 1998). But there are also contradicting results for both cases (Bangma et al., 
2004; Kurek et al., 2004; Stephan et al., 2006a; Steuber et al., 2007a). So far it seems that 
hK2 is most useful in combination with fPSA or other PSA forms. This has been 
supported by studies in screening settings which aimed at the prediction of cancer risk in 
biopsy (Becker et al., 2000b; Nam et al., 2000; Raaijmakers et al., 2007; Vickers et al., 
2010a; Vickers et al., 2008) and also in radical prostatectomy patients for predicting 
cancer aggressiveness and biochemical recurrence of the cancer (Haese et al., 2001; Haese 
et al., 2005; Steuber et al., 2006; Steuber et al., 2007b; Wenske et al., 2009). The 
kallikrein panel including thK2 is discussed in more detail in chapter 2.5.1.   
In these studies, often only thK2 has been measured. Both of the two most commonly 
used immunoassays are for research-use only (Becker et al., 2000a; Blijenberg et al., 
2003; Finlay et al., 2001; Piironen et al., 1996a; Vaisanen et al., 2004). There are 
differences in the assay constructs and standardization (discussed in chapter 2.4.2) which 
may partly explain the contradictory results. The intraindividual variation seems to be 
rather low (Christensson et al., 2011) at least in the short term. There is a lack of 
information on different fhK2 forms and the ability of different assays to recognize them 
or thK2 in equimolar fashion. So far it seems that measuring fhK2 does not offer 
additional information on thK2 (Steuber et al., 2007b; Vaisanen et al., 2004; Vaisanen et 
al., 2006) but the number of studies is so low that no final conclusion can be drawn yet. If 
new information regarding all possible fhK2 forms is discovered fhK2 may again become 
more interesting from a clinical point of view. 
2.4 Challenges with immunoassays 
2.4.1 Immunoassay interference 
Analytical interference is an error in the measurement caused by the sample component 
which is not, by itself, producing a signal in the assay. Immunoassay results may be 
falsely high or low due to different factors. The sample handling (too early centrifugation, 
freezing and thawing) and storage (temperature, time) as well as the nature of the sample 
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(serum or anticoagulated plasma) may affect the measurement. The sample may contain 
fat, debris, clots or aggregates of fiber that interfere with the measurement (Selby, 1999). 
Clinical impact of assay interference 
It is important to recognize the possibility of false results especially when the clinical 
decision depends on the test result. There are unfortunate cases of misdiagnosis and 
mistreatment due to false immunoassay results (Cole et al., 1999; Ismail et al., 2002). The 
problem is pronounced for the very sensitive assays where even a slightest signal is 
significant. 
In the normal clinical setting where men are tested for PSA level a slight increase or 
decrease in the PSA concentration is probably insignificant if the level stays below the 
commonly used thresholds of 3 or 4 ng/mL. If the false signal is markedly high it may 
lead to unnecessary biopsies but as the final decision on treatment is not based solely on 
the PSA value the chance of mistreatment will decrease. Only in the case where the 
prostate cancer patient has been treated by radical prostatectomy and the possible 
recurrence is followed by regular PSA measurements even an increase from 0.01 ng/mL to 
1 ng/mL may cause unnecessary treatment. There are some reported cases where the PSA 
concentration was falsely elevated due to assay interference after a radical prostatectomy 
(Camacho et al., 2002; McAuley et al., 2002; Park et al., 2007) but the patient was 
unnecessarily treated for recurrent cancer only in a few cases (Fritz et al., 2009; Morgan 
and Tarter, 2001).  
Antibody-binding components in blood 
Different antibody binding components in the blood cause interference especially in two-
site immunoassays (Figure 3). A falsely high signal occurs when the tracer antibody is 
bound to the capture antibody through the interfering factor when no antigen is bound to 
the antibodies. A falsely low signal occurs when either the capture or tracer antibody is 
incapable of binding the antigen because of the interfering factors. The most common 
interfering factors are either complement factors or different immunoglobulins produced 
by human immune system. 




Figure 3. Immunoassay interference in two-site immunoassays. The desired signal from 
the complex of antigen and assay antibodies is shown on the far left. Positive assay 
interference bridges the labeled tracer antibodies unspecifically to the capture antibody. 
Negative assay interference prevents the formation of the desired complex by blocking the 
required binding sites of the antibodies. 
 
Complement activation involves binding of the complement proteins to the Fc-part of 
aggregated IgG molecules. It is natural that in immunoassays where a solid phase is 
occupied by stacked IgG molecules the complement may attach to the surface and either 
block the binding of the antigen by steric hindrance and cause a falsely low signal or also 
the tracer antibody forming a bridge resulting in a falsely high signal. (Baatrup et al., 
1986; Kapyaho et al., 1989) 
Rheumatoid factors are human autoantibodies of any class but mainly IgM which 
recognize the Fc part of human immunoglobulins. They may also recognize 
immunoglobulins from other species and thus cause interference in the immunoassays. 
The rheumatoid factors are present in approximately 70% of rheumatoid arthritis patients 
but they are also present in patients with other autoimmune diseases and in about 5% of 
normal population (Courtenay-Luck et al., 1987; Wolfe et al., 1991). 
Heterophilic antibodies are human antibodies of any subclass which bind to any part of 
murine (or other animal) antibody, are of sufficient titer and affinity to have an 
Positive assay interference Negative assay interference
Autoantibodies to antigen
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analytically significant effect and there is no known immunogen (Bjerner, 2005; Kaplan 
and Levinson, 1999). They are differentiated from the specific antibodies against animal 
antibodies (human anti-animal antibodies, HAAA) which are caused by for example 
therapeutic or imaging use of animal antibodies (the immunogen is known) or sometimes 
when the patient has a history of handling animals. The in vivo use of mouse antibodies 
for treatment or diagnostics is common and will cause the immune system to produce 
human anti-mouse antibodies (HAMAs) which may be very specific for the antibody used 
but may sometimes be of less specificity and interfere with the immunoassays even 
though the administered antibody is not used in the assay. (Kaplan and Levinson, 1999; 
Kricka, 1999).  
The heterophilic antibodies are mainly of IgM class and they may be specific to murine 
IgG subclass (Bjerner et al., 2005). Thus they are prone to bind to the tightly stacked 
mouse monoclonal IgGs bound on the solid surface of the assay. They, as well as the 
specific HAMAs, often bind to the Fc part of the antibody (Bjerner et al., 2002; Thorpe et 
al., 2003).   
The frequency estimations of the heterophilic antibodies and HAAAs differ depending on 
the population and assay method used. The reported frequencies vary from 3.4% to 52% 
(Bjerner et al., 2002; Boscato and Stuart, 1986; Frengen et al., 1994; Hawkins et al., 1980; 
Koshida et al., 2010; Ward et al., 1997) and even a prevalence of 0.53% has been reported 
(Ismail et al., 2002) but the latter study was conducted with commercial assays in which 
the interference may have been reduced by blockers in the assay reagents. 
Autoantibodies against the antigen may cause falsely low signals by inhibiting the binding 
of the antigen to the assay antibody. This problem has been found for example in 
immunoassays measuring a cardiac marker troponin I (Eriksson et al., 2005). There are 
also reports of autoantibodies towards PSA both in BPH (Zisman et al., 1995) and prostate 
cancer patients (McNeel et al., 2000) but their impact on the measured PSA levels remains 
uncertain.  
Removing interference  
The most common way to reduce the assay interference is to use different blocker agents 
in the assay buffer. Most unwanted protein-protein interactions are avoided by adding 
bovine serum albumin (BSA) and detergents, such as polysorbates. 
The complement is a problem mainly for fresh serum samples and complement activity 
progressively decreases when the samples are stored at +4 °C or when the samples are 
diluted. Also, as Ca2+ ions are needed to activate the complement the use of EDTA plasma 
prevents the interference caused by the complement. (Kapyaho et al., 1989; Weber et al., 
1990). 
Adding an excess of different immunoglobulins, like bovine gammaglobulin, into the 
assay buffer reduces the interactions between immunoglobulins and proteins binding to 
them (Figure 4). Assays with mouse antibodies usually benefit from an addition of either 
mouse serum or purified unspecific mouse immunoglobulins (often IgG). These scavenger 
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antibodies should prevent the binding of the heterophilic and other antibodies in the 
sample to the assay antibodies. Specific commercial blockers are available, for example 
MAK-33 (Roche Molecular Biochemicals) and HBR (Heterophilic Blocking Reagent, 
Scantibodies) of which MAK-33 is an irrelevant mouse monoclonal IgG and HBR  
a mouse monoclonal IgG against human IgM. Denaturation or polymerization of the 
blocking agents have been found to enhance blocking efficiency (Bjerner et al., 2002; 
Lenz et al., 1990). 
 
Figure 4. Removing immunoassay interference. Scavenger antibodies can be used to 
remove assay interference by having an excess of them together with the sample. The 
interfering factors are expected to bind the scavenger antibodies instead of the capture and 
tracer antibodies. The interfering factors often recognize the Fc part of the antibody and 
thus, the use of capture or tracer antibodies as antibody fragments without the Fc part 
(F(ab')2 or Fab fragments) reduces the assay interference. 
 
Redesigning the assay may help in reducing interference problems. Selecting antibodies of 
different animal origin or subclass has been shown to have some effects  (Hennig et al., 
2000; Larsson et al., 1992) as has the use of chimeric antibodies (Kuroki et al., 1995). The 
most efficient way to reformulate an assay to reduce the interference is to use antibody 
fragments lacking the Fc part because it is the portion to which the complement proteins 
and most of the heterophilic antibodies and rheumatoid factors most often bind. 
Enzymatically produced or recombinant Fab or F(ab')2 fragments as well as recombinant 
scFv fragments have, in several studies, been shown to be effective even though this will 
not eliminate the interference completely (Bjerner et al., 2002; Csako et al., 1988; Vaidya 
and Beatty, 1992; Warren et al., 2005). The most efficient removal of interference is most 
likely accomplished by combining the use of antibody fragments and at least some 
immunoglobulin blocker in the buffer. 
The HAMAs (and other HAAAs) may be very specific for the particular antibody which 
has been administered to the patients and these administered antibodies should not be used 
Capture F(ab’)2 Capture Fab
Rheumatoid factors
Heterophilic antibodies
Tracer Mab, F(ab’)2, Fab
Capture Mab, F(ab’)2, Fab
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in assay constructs. After repeated administrations the HAMAs may develop a specificity 
against the antigen-binding site (idiotype) of the administered antibody and as a 
consequence they may start to compete with the actual antigen for the binding to the assay 
antibodies (Frodin et al., 1992; Reinsberg and Nocke, 1993). This causes negative 
interference which may be very difficult to detect. The situation is similar when there are 
autoantibodies against the antigen. If this is suspected the presence of the anti-idiotypic or 
autoantibodies may be verified by recovery tests with known amounts of the antigen 
added to the sample. If the assay result is significantly different from the expected value 
some kind of negative interference may be present. The only way to achieve the correct 
value is to remove all immunoglobulins from the sample by, e.g., chromatography 
(Turpeinen et al., 1990). 
2.4.2 Standardization and different assay constructs 
PSA 
Many antibodies recognizing PSA were originally raised against fPSA purified from 
seminal plasma and, therefore, they may prefer binding to fPSA instead of PSA-ACT. 
This non-equimolar recognition becomes a problem because samples from patients with 
BPH or other benign conditions have more fPSA and thus the tPSA concentration may 
appear to be higher than the actual value (Semjonow et al., 1996). Similar problems may 
occur in assays in which the binding reactions of antigen to antibody are not allowed to 
reach equilibrium state and if the rate of binding is different for fPSA and PSA-ACT 
(McCormack et al., 1995). The problem of non-equimolarity was one of the main reasons 
different assays to give different tPSA concentrations even for the same sample (Graves, 
1993a; Graves, 1993b). To address this problem 83 PSA antibodies were characterized in 
an antibody epitope mapping workshop which was organized by the International Society 
of Oncology and BioMarkers (ISOBM) in the late 1990's (Stenman et al., 1999).  
A further problem, differential standardization of assays, was another major cause for 
different results and in 2000 WHO launched the First International Standard for PSA 
(free) and also for PSA (90:10). Both originate from seminal plasma and the latter is a 
mixture of PSA-ACT (90%) and fPSA (10%). (Rafferty et al., 2000)  
The use of the WHO calibration has diminished the variation between different assays but 
still the concentrations are not fully interchangeable preventing, for example, the adoption 
of uniform recommendations for tPSA (or F/T PSA) thresholds for biopsy indication (Kort 
et al., 2006; Roddam et al., 2006; Stephan et al., 2006b). The reason for this discrepancy, 
apart from calibration, is most likely in the different assay constructs – different antibodies 
and procedures (Semjonow et al., 2000). For example, antibodies may have different 
affinities and in the procedures the incubation times may vary. 
As stated, there may be clinical consequences of the methodological differences. For 
example, the Beckman Coulter original Hybritech Tandem-R calibration has been widely 
used and now the company is offering both the original and the WHO calibration for their 
PSA assays. By using the WHO calibration the results are approximately 20 to 25% lower 
than using the conventional Hybritech calibration (Fillee et al., 2010; Jansen et al., 2008; 
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Stephan et al., 2008). This would also have clinical implications if the currently used 
threshold for further examinations is not adjusted accordingly. 
There are many statistical models which are used to predict cancer risk before the initial 
biopsy and Stephan et al. studied whether different risk nomograms are predictive if the 
tPSA or fPSA concentrations are measured with an assay different from the one used for 
creating and validating the model (Stephan et al., 2011). The differences were large and 
could lead to unacceptable variation in prostate cancer risk estimations. Especially the 
fPSA measurements seem to be prone to variation, whether calibrated according to WHO 
calibration or not, (Kort et al., 2006; Semjonow et al., 2000; Stephan et al., 2006b; 
Stephan et al., 2011) and thus the calculation of F/T PSA should be made from previously 
studied combinations of assays to draw any conclusions. The fPSA variation in 
measurements may be caused by the differential recognition of the various fPSA forms 
found in blood. In general, each assay should have its own reference ranges and when a 
statistical model is used the assay should be the same that was used for the development 
and validation of the model. The clinical laboratory should inform clinicians if the assay 
method used by the laboratory is changed and provide the PSA concentrations from both 
assays for a while to familiarize the clinician with the new method.  
hK2 
There is no international standard material to calibrate hK2 assays. Recombinant ek-rhK2 
which has mutated pro-sequence to prevent autoactivation (Lovgren et al., 1999), was 
recommended as a potential standard material due to its ability to improve the agreement 
between the Hybritech (Beckman Coulter) thK2 assay and time-resolved fluorometric 
assay for thK2 developed by research groups in Scandinavia (Haese et al., 2003c). There 
are significant differences between the two assays even after common calibration and the 
results are, most likely, not interchangeable. The reason for the differences between the 
assays may be in the possible different hK2 forms in the blood, assay constructs or other, 
for example sample related issues.  
2.4.3 Stability of PSA and hK2 in sample material 
If handled and stored appropriately, total PSA is rather stabile in both serum and 
anticoagulated plasma, even for several years but fPSA seems to be more vulnerable to 
degradation especially in serum (Pettersson et al., 1995; Piironen et al., 1996b; Ulmert et 
al., 2006; Woodrum et al., 1996). Of the different fPSA forms the stability of fPSA-I and 
[-2]proPSA have been studied and they seem to resemble fPSA in their stability 
characteristics, tending to degrade faster in serum. Therefore, either fast measurement, 
freezing or collection of anticoaculated plasma is recommended to retain the protein 
concentration (Nurmikko et al., 2001; Semjonow et al., 2010). 
There is little published information regarding the long-term stability of hK2. The stability 
study made with the Hybritech (Beckman Coulter) hK2 assay suggests that hK2 is rather 
stabile in serum but should be measured soon after blood draw or, for long term storage, 
should be kept at –70 °C (Finlay et al., 2001). For the time-resolved fluorometric assay 
(Vaisanen et al., 2004) the short term stability seemed to be generally good both at +4 °C 
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(over three weeks) and at room temperature (up to 120 h) in either serum or heparin, 
EDTA or citrate plasma. However, hK2 concentration in individual samples could 
fluctuate even up to 2.5 fold during the storage at room temperature (V. Väisänen, 
unpublished results). 
2.5 Diagnostic tools for prostate cancer 
2.5.1 Statistical models 
Regression models and artificial neural networks 
Linear and logistic regression models as well as artificial neural networks (ANNs) are 
some of the most common statistical models used in the studies regarding the prostate 
cancer diagnostics. Linear regression is used not only for calculating standard curves but 
also for estimating whether some other factors (variables) may affect the linear 
relationship of variables x and y. For example, it is known that PSA values increase with 
age and it is possible to fit a linear function to a data set consisting of the PSA 
concentration and age of a group of men (y = a + bx, where y is PSA concentration, x is 
age, a is constant and b is coefficient). It is possible to study whether prostate volume has 
a relationship with PSA concentration when the effect of age is taken into account. This is 
done by adding another variable b2x2 to the equation where b2 is the regression coefficient 
implicating the value or effect of the new variable x2 (prostate volume) in the model. 
There may be several variables and they can be chosen so that only (clinically relevant) 
statistically significant variables are left in the final model. Because linear regression is 
used for studying the association of, for example, biomarkers and linear parameters of the 
disease, it is not usually used to classify individuals into different groups (with or without 
cancer risk etc.). The variables' value in discrimination of groups of individuals may be 
further studied by other methods like logistic regression or ANNs.  
Logistic regression is used to predict a probability of an event which may or may not 
happen, i.e. it has two values (0 or 1). For example, a patient either has a cancer or he does 
not or, the cancer is either organ-confined or non-organ-confined. The function fitted to 
the data is a logistic function f(z) = ez / (1+ ez) where variable z is consisting of i number 
of risk factors bixi (plus the intercept term b0). Again, bi is the regression coefficient 
implicating the effect of each variable in the model. Similarly to linear regression, the 
final model can be chosen to include only statistically (and clinically) significant 
variables. 
ANNs are more complicated functions which have more parameters than logistic 
regression. The possible interaction of variables (i.e. variables are affecting each other) 
and nonlinear relationships are taken into account. The ANN is trained with a set of data 
to find (complex) patterns in the data, and after this learning phase, it can be applied to 
another set of data to predict, for example, the risk of cancer. There is no possibility to 
evaluate the significance of a single variable in the ANN model and in that sense the ANN 
is considered a "black box" (Cammann et al., 2011). 




There is a risk of over-fitting which means that the model may predict the outcome 
perfectly in the training set of data but when it is applied to another set the it does not 
predict the outcome anymore. For this reason there should be a validation data set where 
the outcome is known as in the training set but which consists of new observations. In this 
way the model functionality can be checked independently. Usually the original data set is 
divided into training and validation sets, which means that the number of observations 
needed is rather high. Even if the model has been internally validated in this manner it 
may not be directly applicable to a totally new data set, such as another population. For 
example, the model may have been developed based on European patients but it is not 
self-evident that it will work correctly when used for North American patients due to 
differences in populations. For using the model in another population it has to be validated 
externally for the population in question. 
The quality of a prediction model can be estimated by how good the model is in 
discriminating the two groups (healthy and cancer patients) and how well the model is 
calibrated meaning the extent to which the probabilities predicted by the model actually 
agree with the observed probabilities (or outcomes). Common terms to describe diagnostic 
methods are explained in the Table 4. 
Table 4. The terms used to describe a diagnostic method. 
 
The model's ability to discriminate two groups is commonly visualized with a receiver-
operating characteristic (ROC) curve where sensitivity is plotted against false positive rate 
(1 – specificity) and expressed as the area under the ROC curve (AUC, see Figure 5). The 
AUC of 0.5 means that the model does not discriminate the two groups (the same as a flip 
of a coin). The higher the AUC above 0.5, the better the discriminatory power of the 
models are. The shape of the curve may be different for two models even though the 
AUCs are the same meaning that the models' ability to separate the groups at a given 
sensitivity may be different. This makes the comparison of the models somewhat more 
difficult. Also other relating numbers, for example, positive and negative predictive values 
(PPV and NPV, see Table 4.) and specificities at certain sensitivity levels can be used to 
describe the model performance. The calibration can be evaluated, for example, by 
quantile-quantile plots where the distributions of the predicted and observed probabilities 
are plotted. If the distributions are similar the points align on a diagonal (45°) line. If the 
points do not lie on this line, the position of those points show whether the model under- 
no cancer cancer
Negative predictive value: 
          true negatives           
true negatives + false negatives
Positive predictive value: 
            true positives            
false positives + true positives
Specificity: Sensitivity:
            true negatives                        true positives            
true negatives + false positives false negatives + true positives
Condition ("truth")
Test result
no cancer true negatives false negatives
cancer false positives true positives
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or overestimates the prostate cancer risk, and whether this is general or just in certain 
areas. 
 
Figure 5. Receiver-operating characteristic (ROC) curve and AUC. The ROC curve 
illustrates the discrimination of two groups (patients with and without cancer) by 
parameters, which are in this example the Model 1 (dotted line) and Model 2 (dashed 
line). The reference line (solid line) shows the situation where there is no discrimination. 
The area under the ROC curve (AUC) is in this case 0.5. Of the models, the Model 2 can 
discriminate the two groups better as the line is closer to perfect discrimination (the upper 
left corner) than the line of Model 1. The AUC of Model 2 is higher than that of Model 1 
(exact AUCs have not been calculated). 
Comparing models 
Whether one model discriminates the groups better than the other can be evaluated by 
comparing the AUCs of the two models on same data (or on different data if the models 
are being validated externally). The model with the larger AUC discriminates the groups 
better statistically (see Figure 5). This does not necessarily mean that the other model is 
clinically more useful.  
The clinical value can be evaluated by a decision curve analysis (Vickers and Elkin, 2006) 
which takes into account the fact that each decision will have consequences which may be 
beneficial or harmful and that individuals may weigh those consequences differently.  
A common example of using decision curve analysis is a situation where, after PSA 
measurement (and maybe also some clinical workup), a patient and a clinician consider 
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taken. As biopsy may have some negative consequences some men might want the biopsy 
taken if the cancer risk lies at or above 30% (threshold probability) while some may want 
to be biopsied if the risk lies at 10% or above, i.e. the men weigh the relative harm of a 
false-positive and false-negative predictions differently. The net benefit for each threshold 
probability is estimated by adding up the benefits (true positives) and subtracting the 
harms (false-positives). The latter is weighed by a factor which is derived from the 
threshold probability. In the decision curve (Figure 6) the net benefit is plotted on the  
y-axis and the threshold probability (estimated cancer risk by the model) is plotted on the 
x-axis. The curves of different models, including options of treating (biopsying) all or 
none, are drawn and the model having the highest net benefit at certain (clinically 
relevant) threshold probability or cancer risk (range) is the one that should be used. 
 
Figure 6. Decision curve analysis. The relative harms and benefits of the decision (biopsy 
or not) are expressed as net benefit and the threshold probability (probability to have 
cancer at biopsy) at which one might choose either alternative are plotted on the y- and  
x-axis respectively. In this example, should a man choose biopsy when the prostate cancer 
risk is 20% or higher, Model B would give the best net benefit while Model A would give 
the same result as biopsying all men. 
Models for predicting prostate cancer risk 
The models including PSA measurements in them (most of them are) seem to be tied to 
the PSA assay method (in addition to the population cohort) used while developing them. 
This was noted in a recent study where the predicted probabilities varied significantly if 
PSA values form other assays were applied (Stephan et al., 2011). This is an important 
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Kallikrein panel consists of measured concentrations of tPSA, fPSA, fPSA-I and thK2. A 
laboratory base model including age and tPSA and a clinical model including DRE in 
addition to the subject's age and tPSA were developed using multivariable logistic 
regression and compared with similar models with the additional three kallikrein forms 
(Vickers et al., 2008). The models were developed with the ERSPC screening cohort from 
Gothenburg, Sweden, comprising 740 men undergoing biopsy within the first screening 
round due to elevated tPSA of ≥ 3 ng/mL in order to study the kallikrein panel's ability to 
help in predicting the presence of cancer in the prostate biopsy (192 men had cancer). The 
result was that using this kallikrein panel a significant number of unnecessary biopsies 
could have been avoided. Using a 20% probability of prostate cancer as the threshold, 
57% or 60% of the biopsies could have been avoided using the laboratory or clinical 
models with kallikreins, respectively.  
A low number of cancer cases were missed (31 or 33 of 152 low-grade cases of cancer 
with laboratory and clinical models, respectively) and only few of them were high-grade 
cancers (3 or 1 of 40 high-grade cancer cases). In the decision curve analysis these full 
models including all kallikreins had better net benefit than the base models or base models 
with fPSA over the studied range of threshold probabilities (5–75%). These results were 
later repeated and thus externally validated with another ERSPC cohort form Rotterdam, 
The Netherlands (Vickers et al., 2010a). 
Additionally, the kallikrein panel also predicts the biopsy outcome in recently screened 
men (Vickers et al., 2010b; Vickers et al., 2010c) with elevated tPSA – a subgroup in 
which tPSA (or the base model including age) loses its ability to predict the biopsy 
outcome due to the tPSA based screening. The kallikrein panel has also been applied to 
men with previous negative biopsy (Gupta et al., 2010) and pre-biopsy work-up 
(Benchikh et al., 2010) and again, the number of unnecessary biopsies could be 
significantly reduced with only a few, mostly  low-grade cases of cancer missed. To study 
whether the kallikrein panel would truly help in reducing the over-diagnosis of early-stage 
and low-grade cancers the panel was applied to men who attended the Malmö Diet and 
Cancer study (Manjer et al., 2001) during 1991–1996 by providing a blood sample 
(Vickers et al., 2010e). Their cancer status at the end of year 2005 was used to calculate 
the number of men with tPSA ≥ 3 ng/mL, who would have been advised against biopsy if 
kallikrein panel had been used but who would have developed a clinically diagnosed 
cancer within 5 years after the blood draw. There would have been 21 in 1000 men with 
clinical cancer and only two of them would have been diagnosed with advanced cancer. 
Therefore, the use of the kallikrein panel could also reduce over-diagnosis and the model 
would reduce the number of biopsies by 42%. (Vickers et al., 2010e.) 
As it is notable that the kallikrein panel was developed with screening cohorts and with 
specific immunoassays there is no data on how the panel would work with referral patients 
(even though they might resemble the cohort with previous clinical work-up) or with PSA 
and hK2 concentrations measured with assays from other manufacturers. To date the 
fPSA-I and hK2 assays used in the kallikrein panel are not commercially available unlike 
the models discussed in the following chapters. 
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Prostate health index (phi) is a mathematical function developed by Beckman Coulter. It 
consists of measurement of tPSA, fPSA and [-2]proPSA (with p2PSA assay) and the 
concentrations are combined into a formula: ([-2]proPSA/fPSA) x √tPSA. The phi was 
launched in 2009 and to date only a few studies investigating the clinical significance of 
phi have been published. Generally, the published studies suggest that phi could help in 
discriminating prostate cancer patients from men without cancer (Catalona et al., 2011; 
Guazzoni et al., 2011; Jansen et al., 2010; Le et al., 2010). The increasing phi seems to be 
associated with increasing cancer risk and the AUCs for predicting prostate cancer in 
initial biopsy have been between 0.70 and 0.77, which indicated that phi discriminated 
patients better than using only tPSA or F/T PSA. At sensitivities around 90% the 
specificity of phi was 20–35% (in comparison to specificities of tPSA < 10% and F/T PSA 
10–23%). The phi is to be used only with Beckman Coulter PSA assays and there are 
separate reporting criteria for the Hybritech and WHO calibrated assays. The company 
provides three-class risk classification tables on their web site to help clinicians to 
interpret the phi result (Beckman Coulter, 2012). 
There are also several other prediction models but few of them have been validated 
externally (Schroder and Kattan, 2008; Shariat et al., 2008) and even fewer have gained 
popularity among urologists. The two of the most commonly used models are presented in 
the following chapter because there are user friendly Internet based prediction tools 
available on them. 
2.5.2 From a model to a practical tool 
Nomograms 
A nomogram is a graphical presentation of a statistical model which is made to help the 
use of the model in practice (see Figure 7). Usually there are several segmented 
specifically aligned lines indicating the values which each variable may have, and a line 
where the points corresponding to those values can be seen by drawing a straight line from 
the variable value to the points. Another line indicates the total number of points which is 
aligned with a line where the final probability can be estimated again by drawing a 
straight line from the total points to the corresponding probability. It is possible to make 
the nomogram in different formats, for example as a handheld round disk where each 
layer correspond one variable. The layers are aligned by turning the disks according to 
instructions to obtain the probability of the disease, or prostate cancer as was done with 
ERSPC risk calculator (Kranse et al., 2008).  




Figure 7. A generic example of a nomogram. The points of each variable are read from 
the line at the top. All points are added up and marked on the "Total points" line. The 
probability of the event is read from the bottom line at the position directly below the sum 
total. 
 
The nomograms are usually tied to the characteristics of the population they were 
developed for and also to the variables they include. If a variable is not available it is often 
impossible to calculate the probability and another nomogram without that particular 
variable is needed. This may not be practical as there may be many variables which are of 
different value to different kind of populations. 
The nomogram can also be applied as an Internet based calculator tool as was done with 
the above mentioned ERSPC risk calculator as well as the prediction model based on the 
Prostate Cancer Prevention Trial (PCPT). These risk calculators are discussed below.  
Risk calculators 
ERSPC risk calculators are nomograms of six logistic regression models based on the 
screening cohorts in ERSPC section Rotterdam. The risk calculators provide estimates of 
current prostate cancer risk based on age, family history and urinary complaints in 
calculator 1, tPSA only in calculator 2 and tPSA in combination with DRE, TRUS, 
prostate volume and previous biopsy status in calculators 3 for previously unscreened 
men, 4 for previously screened but not biopsied men and 5 for previously screened and 
biopsied men. The last calculator is intended for the calculation of the probability for 
having a potentially indolent prostate cancer and for aiding in choosing a treatment. 
(Kranse et al., 2008; Roobol et al., 2012; Steyerberg et al., 2007)  The risk calculators 
have been validated externally (Cavadas et al., 2010; Roobol et al., 2009a; Trottier et al., 
2011; van Vugt et al., 2011) and have been shown to help in estimating the risk for an 
individual patient as well as in the decision-making to perform biopsy. Recently it was 
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suggested that the prostate volume estimation, which is made with TRUS for the risk 
calculator, and thus requires equipment and skills to perform, could be replaced by a DRE 
based volume estimation to further ease the use of the calculators (Roobol et al., 2012). 
The calculators are available at www.prostatecancer-riskcalculator.com (accessed 
1.3.2012) where the user fills in the required information on a form after which the 
program reports the estimated risk. They are developed based on Beckman Coulter tPSA 
assay with Hybritech calibration as this was chosen to be the common screening assay in 
ERSPC (Schroder et al., 2009). The sextant biopsy scheme used is also noteworthy, as this 
scheme may not be used anymore and 10- or 12-core schemes may be more common in 
contemporary clinical practice. This might cause the underestimation of the prostate 
cancer risk (Cavadas et al., 2010). 
PCPT risk calculator was based on data of 5519 men who participated in the prevention 
study in its placebo arm (Thompson et al., 2006). The men were primarily healthy and 
their tPSA was below 3 ng/mL. The variables included in the calculator were age (≥ 50 
years), family history, race or ethnicity, status of the possible prior biopsy, DRE finding 
and tPSA concentration (the latter two variables should be no older than 1 year). The 
calculator gives estimates of risks of prostate cancer and high-grade prostate cancer in 
prostate biopsy. The calculator is available at http://deb.uthscsa.edu/URORiskCalc/ 
Pages/uroriskcalc.jsp (accessed 2.3.2012). 
The calculator has been externally validated several times with contradicting results and it 
seems to be generally overestimating the cancer risk if the population to which the model 
is applied differs from the original population with which the model was developed 
(Ankerst et al., 2012). When the PCPT and ERSPC calculators have been compared head-
to-head, the ERSPC calculator has performed better than the PCPT calculator (Cavadas et 
al., 2010; Trottier et al., 2011). The differences in study populations may explain these 
results. 
2.5.3 Future aspects 
The future of prostate cancer diagnostics lies most probably in multiple markers combined 
together within a statistical model. Whether the markers are the ones in the kallikrein 
panel, some newer markers like prostate cancer antigen 3 (PCA3) (Auprich et al., 2011), 
or some combination of protein and genetic markers (Aly et al., 2011) together with 
clinical information remains to be seen. The future of PSA in all of its forms does not 
seem to be threatened and it is likely that it will be measured also in the future. There is 
certainly need for development in the statistical models for them to be truly reliable tools 
for the clinician. The methods for developing a flexible and adaptive risk estimation tool 
may already exist, perhaps in service of a totally different purpose (Vickers et al., 2010d), 
and the innovative adaptation of those methods to diagnostics is just waiting to be 
discovered.  
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3 AIMS OF THE STUDY 
The overall aim of the study was to optimize the immunoassays for fPSA-I, fhK2 and 
thK2 and use those assays to measure the marker concentrations in clinical samples in 
order to study the concentration levels in different cohorts of prostate cancer patients and 
without prostate cancer. Also, a statistical model using the markers was applied to study 
the association of the markers with prostate volume. Finally, a direct immunoassay for 
measuring fPSA-N was developed to improve the analytical performance over the 
calculation method used in previous publications. 
The more detailed aims in the original publications were:  
I To assess whether the assay interference observed in fPSA-I, fhK2 and thK2 
assays could be eliminated by removal of the Fc portion from the capture or tracer 
antibodies. 
II To measure the concentration level of different PSA forms (tPSA, fPSA, fPSA-I 
and calculated fPSA-N) in prostate cancer patients selected for radical 
prostatectomy and study the association of the markers and the pathological stage 
and grade of the cancer.  
III To study the association of four kallikrein markers (tPSA, fPSA, fPSA-I and 
thK2) with prostate volume by applying a statistical model, based on the four 
kallikreins, which predicts the prostate biopsy outcome and to assess whether any 
of the markers or combination thereof could replace the volume measurement in 
predicting the biopsy outcome.  
IV To develop a direct immunoassay for fPSA-N concentration measurements and to 
evaluate its analytical performance. 
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4 SUMMARY OF MATERIALS AND METHODS 
The details of the materials and methods used are described in the original publications  
(I-IV). 
4.1 Clinical samples 
The summary of the different sample panels is described in the Table 5. All samples were 
obtained following standard hospital protocols and ethical procedures accepted by the 
ethical review board of each institution. The following study procedures were in 
accordance with the Helsinki Declaration of 1975, as revised in 1996. As the sample 
processing and storage conditions may affect especially the fPSA concentrations (see 
chapter 2.4.3), these procedures have been described in detail.  
The routine heparin plasma samples collected at Malmö University Hospital (Malmö, 
Sweden) were stored at room temperature for up to 6 h and then transferred to +4 °C for 
1–4 day storage before freezing at –20 °C. All identifying information was removed prior 
to sending the samples to the Department of Biotechnology, University of Turku and no 
clinical information except for gender was attached to the samples. fPSA, fPSA-I, thK2 
and fhK2 concentrations of the samples were measured to find the samples with potential 
assay interfering factors (I). The selected samples were used to further study the 
interference problem. The samples used for studying interference fPSA-N (unpublished) 
were similar to other routine samples except that the immunoassay measurements were 
performed at Malmö University Hospital before the pooling at the Department of 
Biotechnology. 
The routine serum samples collected at Turku University Hospital were without any 
identifying information and were collected identically to the routine samples at Malmö 
University Hospital. These samples were used to evaluate the optimized immunoassay 
protocols (I). 
The clinically defined anti-coagulated plasma samples were collected from consecutive 
men that underwent clinical work-up due to their symptomatic prostate condition at the 
Department of Urology at Turku University Hospital. The samples were taken before 
biopsy or initiation of treatment, centrifuged within 3 h of the blood draw and stored at  
–20 °C. The samples were used to evaluate the optimized immunoassays (I), to study the 
pre-operative fPSA forms concentrations in radical prostatectomy patients (II) and to 
evaluate the fPSA-N immunoassay (IV). 
The samples collected for the European Randomized Study of Screening for Prostate 
Cancer (ERSPC) were processed within 3 h of the venipuncture at the Rotterdam 
University Hospital, Rotterdam, The Netherlands and at the Sahlgrenska University 
Hospital, Göterborg, Sweden where they were stored at –80 °C and –20 °C, respectively. 
The samples were shipped in a frozen state to Malmö University Hospital where the 
kallikrein measurements were performed (III). 
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The plasma samples collected from healthy volunteers at the Department of 
Biotechnology were centrifuged within 1 h of the venipuncture and stored at –20 °C. The 
samples were used for fPSA-N immunoassay evaluation (IV). 
Table 5. Description of the samples used in the studies. Samples obtained from one 





Matrix Gender Number of 
samples 









I assay interference 
studies 
   female 31 (8) 












plasma male 138 
I assay interference 
studies 
    111 II fPSA forms in rp
a 
patients 
    13 (5) 
IV fPSA-N assay 
evaluation (recovery 
study) 
  EDTA plasma male 111 
I assay interference 
studies 
    198 II fPSA forms in rp
a 
patients 















serum male 740 III kallikreins and prostate volume 







IV fPSA-N assay 
evaluation 
a rp, radical prostatectomy  
b UTU/BT, University of Turku, Department of Biotechnology 
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4.2 Antibodies and standard materials 
4.2.1 Monoclonal antibodies (Mabs) 
The monoclonal antibodies used are listed in the Table 6. 
Table 6. The monoclonal antibodies (Mab) used in the studies. 
Mab Specificity Immunoassay Publication Reference 
11B6 fhK2 fhK2 capture I-III (Vaisanen et al., 2004) 
2C1 tPSA, thK2 fPSA-N, 
fPSA(2C1)b, 
tPSA(2C1)b 
tracer in all 
IV (Pettersson et al., 1995) 





I-IV (Nurmikko et al., 2000) 
5A10 fPSA fPSA tracer I-IV (Lilja et al., 1991) 
5A10 Fab fPSA fPSA-I, 
fPSA-N, 
fPSA(2C1)b 
capture in all 
I-IV (Eriksson et al., 2000) 
5F7 tPSA thK2 blocker I-III (Nurmikko et al., 2000) 
5H6 tPSA thK2 blocker I-III (Nurmikko et al., 2000) 




I-III (Becker et al., 2000a) 
7G1 tPSA, thK2 thK2 tracer I-III (Nurmikko et al., 2000) 
H117 tPSA, thK2 tPSA, 
tPSA(2C1)b 
fPSA 
capture in all 
I-IV Abbot, USA  
Characterized in (Eerola et al., 
1997; Piironen et al., 1998) 
H50 tPSA, thK2 tPSA tracer I-III Abbot, USA  
Characterized in (Eerola et al., 
1997; Piironen et al., 1998) 
a Mab 6H10 has 5% cross-reaction with tPSA (with 20 times lower affinity) 
b tPSA(2C1) and fPSA(2C1) are assays made in parallel with fPSA-N assay 
4.2.2 Antibody fragments 
Preparation of F(ab´)2 fragments 
To reduce the immunoassay interference the Mabs 11B6 and 6H10 were digested to 
F(ab')2 fragments with bromelain treatment (I) which results in removal of the Fc part of 
the Mab. The bromelain containing ID-Diluent 1 (Diamed, USA) was added to the Mab in 
0.5 M Tris-HCl, pH 7.0, 1 M NaCl, 30 mM EDTA (32 µL of Diluent for each mg of Mab) 
and incubated for 2 h at +37 °C. The reaction was stopped by adding 1/10 reaction volume 
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of freshly made 0.2 M ethylene maleimide. The F(ab')2 fragments were purified as 
described in chapter 4.2.3. 
Recombinant 5A10 Fab fragment 
The recombinant 5A10 Fab fragment was cloned from the monoclonal hybridoma cell line 
as described by Eriksson et al. (Eriksson et al., 2000). The Fab fragment containing 
expression vector pKK incorporated C-terminal cysteine and hexahistidine tag to the Fab 
fragment which provided the purification site and enabled the site-specific biotinylation.  
The recombinant 5A10 Fab fragment was expressed into the periplasmic space of Escherichia 
coli strain RV308 in a 4 L batch fermentation (BioFlow3000 fermentor, New Brunswick 
Scientific, USA)  in SB medium (30 g/L tryptone, 20 g/L yeast extract, 10 g/L MOPS, pH 7.0) 
supplemented with 0.1 g/L ampicillin, 0.2% glucose and 2 mM MgSO4. The inoculation was 
done when the cells were at exponential growth phase. The cells were grown overnight at  
+26 °C to OD600 of 4 after which the production of the Fab was induced by adding isopropyl 
β-D-1-thiogalactopyranoside (IPTG) to 100 µM. The growth was monitored by OD600 and 
oxygen consumption and the cells were harvested by centrifugation when the growth started to 
decrease. The cell pellets were stored at –70 °C prior to purification. 
The purification was done essentially as previously described (Korpimaki et al., 2004). 
Briefly, the cells were lysed by Tris buffer extraction based on osmotic shock. The Fab 
fragment was purified first with cation exchange chromatography with Streamline SP 25 
(GE Healthcare, USA) and then using immobilized metal affinity chromatography  
(Ni-NTA Agarose, Qiagen, Germany). The biotinylation of the free cysteines at the Fab 
C-terminus was done while the Fab fragments were bound in the Ni-NTA column by 
circulating 400 µM EZ-Link PEO-maleimide activated biotin (Thermo Scientific, USA) 
through the column for 2 h. Finally, the buffer was changed to TSA buffer (50 mM Tris-
HCl, pH 7.75, 150 mM NaCl, 0.5 g/L NaN3) with desalting column (GE Healthcare) and 
bovine serum albumin (BSA) was added to 1 g/L to enhance stability. 
4.2.3 Purification, biotinylation and labeling of Mabs and antibody 
fragments 
The Mabs produced by the hybridoma cells and the enzymatically digested F(ab´)2 
fragments were purified with Protein G column (GE Healthcare Life Sciences, UK) which 
was equilibrated with 20 mM sodium phosphate buffer, pH 7.5. Elution of the bound 
antibody or F(ab’)2 fragment was done with 0.1 M glycine, pH 2.7. The pH was 
immediately neutralized by collecting the fractions on 1/10 of the fraction volume of 1 M 
Tris-HCl, pH 9. The antibody or F(ab’)2 fragment containing fractions were pooled by 
their absorbance at 280 nm and the buffer was changed to 0.9% NaCl before further 
modifications. The purity of the F(ab’)2 fragments were verified by running a sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE).  
The antibodies and their F(ab’)2 fragments were biotinylated using 40–60-fold molar 
excess of biotin isothiocyanate in 50 mM NaHCO3, pH 9.8. The reaction was incubated at 
room temperature for 4 h after which the excess biotin was removed by changing the 
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buffer twice with desalting columns (GE Healthcare) equilibrated and eluted with TSA 
buffer, pH 7.75. To enhance the stability BSA was added to 1 g/L. 
The antibodies and their F(ab’)2  fragments were labeled with 50–200-fold molar excess of 
N1 europium(III) chelate (N1-(4-isothiocyanatobenzyl)diethylenetriamine-N1,N2,N3,N4-
tetracis(acetic acid) in 50 mM NaHCO3, pH 9.8. The reaction was incubated overnight at 
+4 °C (room temperature for Mab 7G1) after which the unreacted chelate was removed by 
gel filtration with Superdex 200 HP column (GE Healthcare) equilibrated and run with 
TSA, pH 7.75. The fractions containing the antibody were pooled by the absorbance of the 
fractions at 280 nm and BSA was added to 1 g/L. 
4.2.4 PSA and hK2 
The recombinant proPSA and ek-hK2 (mutated pro-sequence to enhance stability) used as 
immunoassay standard material were produced using a baculovirus expression system 
Trichoplusia ni (High Five) as described previously (Lovgren et al., 1997; Rajakoski et 
al., 1997). The proteins were purified with affinity chromatography. AffiGel 10 support 
matrix (Bio-Rad, USA) was coupled with the monoclonal antibody 5A10 for proPSA and 
11B6 for ek-hK2 purification. The columns were equilibrated and run with 50 mM Tris, 
pH 7.2, 0.5 M NaCl and the elution was done with 0.2 M glycine, pH 2.5. The fractions 
were neutralized by collecting the eluted proteins on 1/10 of the fraction volume of 1 M 
Tris-HCl, pH 9. 
The dilutions of the standard material were made in TSA, pH 7.75, with 1 g/L protease-
free BSA. The concentrations were calibrated against World Health Organization (WHO) 
free PSA standard (Rafferty et al., 2000) using the tPSA immunoassay (chapter 4.3.3) 
which recognizes PSA and hK2 with equal affinity (Lovgren et al., 1995). The 
concentration range was from 0.006 ng/mL to 570 ng/mL (6 dilutions) for proPSA and 
from 0.0034 ng/mL to 3.4 ng/mL (7 dilutions) for ek-hK2. For the tPSA and fPSA assays 
performed in Malmö University Hospital the standard material included in the Delfia 
Prostatus PSA F/T Dual Assay kit (Perkin-Elmer Life Sciences, USA) was used. 
The seminal plasma PSA pools A, B, C, D and E, used for fPSA-N immunoassay 
evaluation, were a kind gift from Professor Ulf-Håkan Stenman (Department of Clinical 
Chemistry, University of Helsinki, Helsinki, Finland). They were fractionated by anion 
exchange chromatography as described by Zhang et al. (Zhang et al., 1995). The pools A 
and B contained only intact PSA with different glycosylation (Mattsson et al., 2008), C 
and D mostly internally cleaved forms (20% and 10% of intact PSA respectively) and pool 
E was 95% internally cleaved PSA (5% of intact PSA). 
4.3 Immunoassays 
4.3.1 General immunoassay protocol 
All immunoassays were conducted on streptavidin coated 96-well microtitration plates 
(Innotrac Diagnostics, Finland or Kaivogen Oy, Finland) either with 1235 Automatic 
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immunoassay system AutoDelfia (Perkin-Elmer Life Sciences) or manually. The 
following basic protocol was used unless otherwise stated. The assays were performed in 
three steps with 1 h incubation at room temperature with slow shaking. The plates were 
washed twice after capture antibody and sample incubations and four times after label 
incubation. The enhancement solution (200 µL/well) was incubated 5 to 10 min at room 
temperature with slow shaking before time-resolved europium fluorescence measurement 
by AutoDelfia or with Victor 420 Multilabel Counter (Perkin-Elmer Life Sciences). The 
concentrations of the unknown samples were calculated using MultiCalc software version 
2.52 (Perkin-Elmer Life Sciences). The assay buffers used in each assay are described in 
the following chapter (4.3.2). 
4.3.2 Assay buffer 
All assays had a common assay buffer containing 50 mM Tris-HCl, pH 7.75, 150 mM 
NaCl, 0.05% NaN3, 0.01% Tween 40, 0.05% bovine gammaglobulin, 20 µM diethylene 
triamine pentaacetate, 0.5% bovine serum albumin and 20 mg/L cherry red. This buffer 
was used without supplements for the capture antibody dilutions. The bovine IgG reduces 
some of the unspecific reactions but for sample and label incubations the buffer was 
supplemented with different blocking agents to further reduce the heterophilic interference 
originating from the sample matrix.  
For total and free PSA immunoassays the assay buffer was supplemented with 5 µg/mL 
native mouse IgG, 5µg/mL MAK-33 monoclonal antibody (Roche Applied Science, 
Switzerland), 5 µg/mL heterophilic antibody blocking agent HBR-2 (Scantibodies 
Laboratory, USA) and 100 U/mL heparin. 
For the original thK2 assay the assay buffer was supplemented with 10 mg/L native mouse 
IgG, 5 mg/L denatured mouse IgG and 10 mL/L mouse serum and for the fhK2 assay with 
10 mg/L native mouse IgG and 25 mg/L denatured mouse IgG. For the original fPSA-I 
assay the assay buffer was supplemented with 10 mg/L native mouse IgG and 5 mg/L 
denatured mouse IgG. The composition was changed during the assay optimization 
process as described below. 
In the study of assay interference (I) the initial screening of samples was performed with 
assay buffer without supplements but the above mentioned blockers as well as mouse 
serum and unspecific monoclonal antibodies were tested both in their native and heat-
denatured forms and in different combinations during the optimization process. The heat-
denaturation of the different blockers was performed at 63 °C for 30 min. The optimized 
thK2, fhK2 and fPSA-I assays were made with an assay buffer supplemented with  
25 mg/L denatured mouse IgG. This buffer was also applied to fPSA-N assays as well as 
the tPSA(2C1) and fPSA(2C1) assays performed in parallel with the fPSA-N assay. 
4.3.3 Total and free PSA immunoassays (I–IV) 
The tPSA and fPSA concentrations were measured using in-house immunoassays (I, II, 
IV) except for the measurements made at Lund University Hospital in Malmö which were 
performed using Delfia Prostatus PSA F/T Dual Assay (Perkin-Elmer Life Sciences) (III). 
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The capture antibody for both assays was biotinylated H117 (300 ng/well in 100 µL of 
assay buffer in each well). The proPSA standards and samples were added in 25 µL 
volume on 100 µL of assay buffer in each well. The europium labeled tracers were H50 
Mab for tPSA assay and 5A10 Mab for fPSA assay (both 100 ng/well in 200 µL of assay 
buffer per well). 
4.3.4 Intact fPSA immunoassay (I–IV) 
Recombinant 5A10 Fab fragment, which was site-specifically biotinylated to its  
C-terminal cysteine, was used as the capture antibody (150 ng/well in 100 µL of assay 
buffer). The proPSA standards and samples were added in 50 µL volume on 100 µL of 
assay buffer per well. The europium labeled Mab 4D4 was used as tracer (200 ng/well in 
200 µL of assay buffer per well). 
The original assay protocol used for measuring the Göteborg cohort (III) was performed 
with a different buffer (see 4.3.2). The capture antibody was the intact, biotinylated 5A10-
Mab (200 ng/well in 200 µL assay buffer), and the sample incubation was done with  
0.5 µL of mouse serum in 100 µL of assay buffer in each well for 2 h. The label 
incubation and measurement were done as in the optimized assay. 
4.3.5 Nicked fPSA immunoassay (IV) 
Calculated fPSA-N concentrations 
The calculated concentrations of fPSA-N were used in publications II-IV. The calculation 
was done by subtracting the fPSA-I concentration from fPSA concentration. If the fPSA-I 
concentration was higher than fPSA concentration the fPSA-N concentration was set to 
0.001 ng/mL and the I/F PSA ratio to 100% for statistical analysis. 
Interference in fPSA-N immunoassay (unpublished) 
Based on the interference problems seen in fPSA-I immunoassay it was hypothesized that 
interference would also be a similar problem in fPSA-N immunoassay as the capture 
antibody is the same. This was verified by measuring three pools of female samples 
(consisting of 9, 10 and 12 samples, Table 5.), known to produce falsely high signals in 
fPSA-I immunoassay, with fPSA-N immunoassay and fPSA(2C1) immunoassay made in 
parallel with a similar protocol with both Mab and Fab capture antibodies with assay 
buffer supplemented with heat-denatured mouse IgG. 
fPSA-N immunoassay and fPSA(2C1) and tPSA(2C1) immunoassays made in parallel  
The fPSA-N immunoassay principle is illustrated in Figure 8A. The biotinylated 
recombinant 5A10 Fab fragment was used as the capture antibody (150 ng in 25 µL of 
assay buffer per well) and the proPSA standards and samples were added in 50 µL volume 
on top of 50 µL of assay buffer and incubated for 2 h at room temperature with slow 
shaking. After two washes, 5000 ng of 4D4 Mab was added in 50 µL of assay buffer in 
each well to block all intact PSA. The plate was sealed with a tape and incubated 
overnight at +4 ºC without shaking. After incubation without a washing step the europium 
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labeled 2C1 tracer Mab was added (100 ng in 50 µL of assay buffer per well) and the 
incubation was continued for 4 h at +4 ºC. After four washes the measurement was made 
as described above (chapter 4.3.1). 
In order to obtain fPSA and tPSA concentrations, which would be comparable to fPSA-N 
concentrations, similar protocols were used to measure the concentrations of fPSA and 
tPSA in parallel with fPSA-N immunoassay (see Figure 8B and C). The biotinylated 
capture antibodies were the recombinant 5A10 Fab fragment (150 ng/well) in fPSA(2C1) 
assay and H117 in tPSA(2C1) assay (300 ng/well), both applied in 25 µL of assay buffer 
in each well. The sample incubation was done as in fPSA-N assay but instead of blocker 
Mab 4D4, only assay buffer was used. The tracer in both assays was europium labeled 
2C1 Mab as in the fPSA-N assay.  
 
Figure 8. The principle of the direct fPSA-N immunoassay and the assays for fPSA and 
tPSA measurements. A) fPSA-N assay. B) fPSA(2C1) the standard curve of which was 
also used for calculating fPSA-N concentrations (see text for details). C) tPSA assay. 
cPSA = complexed PSA. The fPSA(2C1) and tPSA(2C1) assays were made in parallel 
with the same overall protocol to obtain comparable concentrations (IV, unpublished). 
 
The fPSA(2C1) immunoassay standard curve was used to calculate the fPSA-N 
concentrations because the standard material, intact proPSA, was blocked in the fPSA-N 
assay. The standard curve in the fPSA-N assay was used to calculate the efficiency of the 
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4D4 blocking. The specific signal of each calibrator dilution in fPSA-N assay was divided 
by the corresponding signal in the unblocked fPSA(2C1) assay, the resulting ratio was 
then subtracted from 1 and multiplied by 100% to obtain the blocking efficiency for the 
particular calibrator dilution in each run. Because the blocking was not perfect, the 
average blocking efficiency of all calibrator dilutions was used to correct the fPSA-N 
concentrations for this cross-reaction with fPSA-I. 
4.3.6 Total and free hK2 immunoassays (I–III) 
Biotinylated 6H10-F(ab’)2 fragment was used as the capture antibody (300 ng in 100 µL 
of assay buffer per well). The recombinant ek-hK2 standards and samples were added in 
100 µL volume on 100 µL of assay buffer per well with PSA specific antibodies 2E9 
(1000 ng/well), 5F7 (1000 ng/well) and 5H6 (500 ng/well). The blocker antibodies had 
epitopes overlapping with the epitopes of the capture and tracer antibodies minimizing the 
cross-reaction of PSA. The europium labeled tracer 7G1 Mab was added (100 ng) with 
blocker Mab 5H6 (500 ng) in 200 µL of assay buffer in each well. The measurement was 
made as described above. 
The original thK2 assay was made as the optimized assay described above except that the 
buffer described in chapter 4.3.2 was used, capture antibody was the intact, biotinylated 
6H10-Mab (300 ng/well in 100 µL assay buffer) and the sample incubation was 2 h 
instead of 1 h. 
Biotinylated 11B6-F(ab’)2 fragment was used as the capture antibody (300 ng in 100 µL 
of assay buffer per well). The recombinant ek-hK2 standards and samples were added in 
100 µL volume on 100 µL of assay buffer per well. The tracer was europium labeled 
6H10-F(ab’)2 fragment (100 ng in 200 µL of assay buffer per well). The measurement was 
made as described above. 
The original fhK2 assay differed from the optimized protocol by the buffer (see chapter 
4.3.2), and by the capture and tracer antibodies being intact Mabs instead of F(ab’)2 
fragments. Furthermore, for the capture, biotinylated 11B6-Mab was used 300 ng/well in 
100 µL of assay buffer and the sample incubation was 2 h instead of 1 h in the optimized 
assay. 
4.4 Statistical analyses 
Statistical calculations were performed with R software, version 2.0.1 (R Development 
Core Team, 2005) (II), GraphPad Prism, version 4.03, for Windows (GraphPad Software, 
San Diego CA) (II and IV) or Stata 10.0/11.0 (StataCorp, College Station, TX) (III). The 
two-sided P-values < 0.05 were considered to be statistically significant. The correlations 
of different analytes and clinical or pathological attributes were studied with Spearman's 
rank correlation (II, III). The comparisons between different groups of patients were 
made from log-transformed marker concentrations with analysis of variance (II). 
Multivariable logistic regression was used to fit the predictive models based on kallikrein 
and clinical measurements in both training and validation sets (cohort randomly divided in 
a 1:3 ratio in Rotterdam and 2:1 in Göteborg, respectively) (III). tPSA and fPSA were 
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entered into the logistic models using restricted cubic splines to account for nonlinearity. 
The comparison of calculated and measured fPSA-N concentrations in patient samples 
was made with Deming (type II) regression analysis (IV).  
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5 SUMMARY OF RESULTS 
5.1 Removal of assay interference 
5.1.1 Interference rate (I)  
Female (n=1092) and male (n=957) routine heparin plasma samples were screened to 
select samples with interference. Female samples were measured with fPSA-I and fhK2 
assays and male samples with fPSA-I, fPSA, fhK2 and thK2 assays, all in singlicates. The 
assay buffer contained no other scavenger antibodies in addition to the bovine IgG. The 
interference was defined as fPSA-I or fhK2 concentrations above 0.01 ng/mL in female 
samples and ratios of I/F PSA and F/T hK2 above 1 in male samples. The observed 
interference rates are shown in Table 7.   
Table 7. Number of heparin plasma samples exhibiting falsely high signals in initial 
screening. "Both" is the number of samples having interference in both fPSA-I and hK2 
assays (I).  
Female samples n=1092 n %  Male samples n=957 n % 
fPSA-I > 0.01 ng/ml 350 32%  I/F PSA > 1 165 17% 
fhK2 > 0.01 ng/ml 427 39%  F/T hK2 > 1 335 35% 
Both 270 25%  Both 108 11% 
Total interference 507 46%  Total interference 392 41% 
 
5.1.2 Blocking components in the assay buffer (I) 
Several different blocking agents were tested for their capability to decrease the 
interference. The heat-denatured mouse IgG as 25 mg/L concentration was the best among 
the tested blockers and their combinations. In some samples the presence of blockers 
caused the false signal to rise even higher. This was especially evident when the blockers 
were in their native form (native mouse IgG, mouse serum or untreated MAK-33). Despite 
adding the blockers into the assay buffer about 30% of the pre-selected samples still had 
interference. 
5.1.3 Optimization of the capture and tracer antibodies (I) 
Several samples were depleted during the optimization process and therefore the number 
of tested samples decreased in each step. The Mabs were changed to F(ab’)2 or Fab 
fragments to reduce the interference caused by the interfering molecules attaching to the 
Fc-part of the Mab. 
Female samples 
Of the 78 samples having interference in fPSA-I assay with Mabs 33 (42%) had signal 
levels above 0.01 ng/ml after changing the capture Mab to recombinant Fab fragment and 
only 4 (5%) samples had elevated signals when the buffer with 25 mg/L denatured mouse 
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IgG was combined with the Fab-based assay. Changing both capture and tracer Mab in the 
fhK2 assay decreased the number of interference samples to 3 in 157 (2%) previously high 
signal samples. The use of 25 mg/L of denatured mouse IgG decreased the fhK2 signals 
but 3 (2%) samples remained above 0.01 ng/mL. 
Male samples 
Male samples having I/F PSA or F/T hK2 ratios above 1.5 were considered to have high 
interference and were used in optimization to ensure that the elevation in signal level is 
caused by the interference and not by assay variation. Of the 957 samples, high 
interference was found in 183 (19%) samples. The I/F ratio was high in 42 samples, the 
F/T hK2 ratio was high in 90 samples and both ratios were high in 51 samples. 
Changing the fPSA-I assay capture Mab to Fab fragment reduced the number of samples 
with I/F PSA ratio > 1 to 11/47 (23%) and using the assay buffer with 25 mg/L denatured 
mouse IgG further reduced it to only 2/47 (4%) samples with interference. 
Using F(ab’)2 fragments in fhK2 assay reduced the number of samples with F/T hK2 > 1 
to 25/140 (18%) and with the buffer containing 25 mg/l denatured mouse IgG the number 
was 15/96 (16 %). When also the capture Mab of thK2 assay was changed to F(ab’)2 
fragment the F/T hK2 ratio was above 1 in 9/96 (9 %) samples and combining both 
optimized assays with the optimized assay buffer containing the mouse IgG further 
reduced the number of interference samples to only 3/96 (3%). 
Based on these results the optimized assay formats were as stated in Table 8 and in 
chapter 4.3. These assays were used in further studies. 
Table 8. The screening and optimized assay formats (I). 
 
 Screening assay Optimized assay 
  fPSA-I fhK2 thK2  fPSA-I fhK2 thK2 
Capture and tracer antibodies       
 Biotinylated capture Mab Mab Mab  Fab F(ab’)2 F(ab’)2 
 Eu-labeled tracer Mab Mab Mab  Mab F(ab’)2 Mab 
Blocking antibodies in the assay buffer       
 Bovine IgG Yes Yes Yes  Yes Yes Yes 
 Denatured mouse IgG No No No  Yes Yes Yes 
 
5.1.4 Evaluation of optimized assays (I–III) 
The optimized assays were evaluated by measuring EDTA plasma, heparin plasma and 
serum samples with the original and optimized assays (Table 8). The results are shown in 
Table 9.  
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The number of samples having I/F PSA and F/T hK2 ratios above 1 was reduced 
significantly when the optimized assays were used. Also, the magnitude of the 
interference was decreased. In the non-optimized fPSA-I assay the concentrations in 
interference samples were generally up to 30 times higher than the fPSA concentrations, 
while in the optimized fPSA-I the concentrations in the remaining interference samples 
were only up to 3 times higher than the fPSA concentrations. The change in the hK2 
assays was similar; the F/T hK2 ratios were up to 145 in non-optimized assays while in 
the optimized assays only 6-fold difference was seen. In addition to this, the remaining 
interference was in the low concentration range near the limit of quantification in all 
assays. 
The number of interfering samples was low also in the later studies (II, III) as shown in 
Table 9. Notably, in the ERSPC Rotterdam cohort the I/F PSA was above 1 in only 6 out 
of 2914 serum samples (0.2%). Only thK2 was measured from the samples so no data is 
available for the hK2 assay interference rate in this cohort. 
Table 9. Evaluation of the optimized assays and interference rate in sample panels 
measured in the optimized assays. See details of the sample panels from Table 5 (I–III, 
unpublished). 





 Fab- or F(ab’)2- 
based assay 
  n  n %  n % 




serum 171  24 14  5 3 
heparin 122  19 16  2 2 
EDTA 94  9 10  1 1 
Turku, clinically defined  
rp patients (II)a 
heparin 111     0 0 
EDTA 198     5 3 
Rotterdam (III) serum 2914     6 < 1 
   




serum 171  14 8  7 4 
heparin 138  21 15  8 6 
EDTA 111  28 25  5 5 
Turku, clinically defined 
rp patients (II)a 
heparin 111     4 4 
EDTA 198     8 4 
a rp, radical prostatectomy 
5.1.5 Interference in fPSA-N assay (unpublished) 
The effect of interfering factors on fPSA-N immunoassay, described in chapter 5.4 (IV), 
was tested using three pools of female heparin plasma known to have interference in 
fPSA-I assay based on measurements made at Malmö University Hospital. Two out of 
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three pools showed a signal above 0.02 ng/mL in fPSA-N assay and all three in 
fPSA(2C1) assay made in parallel when the Mab capture antibody was used. When the 
capture Mab was changed to Fab fragment, all three pools were below 0.02 ng/mL in 
fPSA-N assay and only one pool had a concentration of 0.05 ng/mL in fPSA(2C1) assay. 
In further fPSA-N, fPSA(2C1) and tPSA(2C1) assays the Fab fragment was used as the 
capture antibody and 25 mg/L heat-denatured mouse IgG was added to the assay buffer.  
5.2 fPSA isoforms in radical prostatectomy patients (II) 
The clinical value of preoperative fPSA-I and calculated fPSA-N in predicting the 
pathological features of prostate cancer was studied in 309 men scheduled to undergo 
radical prostatectomy at Turku University Hospital. The median fPSA-I concentration was 
0.42 ng/mL and it constituted 59.8% (median value) of fPSA and 5.7% of tPSA while 
fPSA-N median concentration was 0.28 ng/mL constituting 40.2% of the fPSA and 3.6% 
of the tPSA in the plasma. Median fPSA concentration was 0.70 ng/mL and the median 
F/T PSA ratio was 9.7%. 
The tPSA concentrations between 4 and 10 ng/mL have been considered to represent a so 
called "gray zone" because the cancer risk estimation is even more difficult than with the 
extremely high or low concentrations (Catalona et al., 1998; Catalona et al., 1994). 
Therefore, we also analysed the subgroup of patients with tPSA concentrations below  
10 ng/mL. 
Generally, the ratios of N/T PSA and F/T PSA were lower in patients with more advanced 
pathological features. These ratios had the strongest negative correlations with pathologic 
stage, WHO grade and Gleason score, though the correlations were modest (between  
–0.205 and –0.262). In addition to N/T and F/T PSA ratios, also fPSA-N as the only single 
marker correlated with Gleason score in patients with tPSA < 10 ng/mL. 
The individual markers could not separate different groups based on pathological TNM 
stage. I/T PSA could statistically separate pT2b group from pT3a group and N/T PSA 
pT3a and b groups from each other and F/T PSA was statistically different in both cases 
(Figure 9). I/T PSA was able to separate the two groups also in patients with tPSA  
< 10 ng/mL. When the groups were combined to organ-confined (pT2) and non-organ-
confined (pT3) groups, all three ratios and tPSA as the only single marker had statistically 
significant p-values (all < 0.01). In patients with tPSA < 10 ng/mL the difference 
remained significant only for tPSA and F/T PSA.  




Figure 9. Box plot distributions of PSA isoform concentrations (A) and their ratios (B) in 
prostate cancer patients with different pathological TNM stage (unpublished). Boxes 
show median (line inside the box) and 25th and 75th percentiles (limits of the box). 
Whiskers show 10th and 90th percentiles. A) None of the markers could statistically 
separate different patient groups. Number of patients in the groups: pT2A, n = 52; pT2B,  
n = 94; pT3A, n = 130 and pT3B, n = 25. B) All ratios were able to differentiate at least 
two consecutive groups (the analysis of variance p-values < 0.05 shown). Number of 
patients in the groups: pT2A, n = 50; pT2B, n = 89; pT3A, n = 127 and pT3B, n = 25. 
 
The ratios were also able to statistically separate patients with different grades of cancer. 
N/T PSA was able to statistically separate all WHO groups, while F/T PSA was 
significantly different only in groups 2 and 3. Both ratios were able to separate patients 
with Gleason score < 7 from patients with Gleason score 7 as shown in Figure 10.  
N/T PSA, I/T PSA and fPSA-N as the only single marker were able to separate the groups 
also in patients with tPSA < 10 ng/mL. Furthermore, the trend of the decreasing median 
ratios with increasing Gleason score is seen in Figure 10.  
It has been suggested that the prognosis of Gleason score 7 patients whose primary 
Gleason grade is 3 or lower is better than of the patients with primary Gleason grade 4 or 
higher (Lilleby et al., 2001; Steinberg et al., 1997). We divided the patients with Gleason 
score 7 into two new groups: The group 7a included the patients with primary Gleason 
grade ≤ 3 and the group 7b included the patients with primary Gleason grade ≥ 4. These 
two groups were further combined with other patients to create a low-grade group with 
Gleason scores from 3 to 7a and a high-grade group with Gleason scores from 7b to 9. 
tPSA and all ratios, except for I/F PSA, were able to differentiate the groups. In patients 
with tPSA < 10 ng/mL only fPSA-N concentration and F/T PSA were different in each 
group. N/T PSA had a borderline significant p-value of 0.052.  




Figure 10. Box plot distributions of fPSA isoforms (A) and their ratios (B) in prostate 
cancer patients with different Gleason scores (unpublished). Boxes show median (line 
inside the box) and 25th and 75th percentiles (limits of the box). Whiskers show 10th and 
90th percentiles. A) None of the markers could statistically separate different patient 
groups. Number of patients in different groups: Gleason score < 7, n = 190; Gleason score 
7, n = 82 and Gleason score > 7, n = 36. B) F/T PSA and N/T PSA could separate patients 
with Gleason score < 7 from patients with score 7 (the analysis of variance p-values < 
0.05 shown). Number of patients in different groups: Gleason score < 7, n = 182; Gleason 
score 7, n = 78 and Gleason score > 7, n = 35. 
 
5.3 Kallikrein panel and prostate volume (III) 
A previously developed statistical model based on the measurement of tPSA, fPSA, fPSA-
I and thK2 concentrations was shown to be a strong predictor of biopsy outcome in men 
with elevated tPSA (Vickers et al., 2010a; Vickers et al., 2008). In the current study, the 
effect of adding digital rectal examination (DRE) and prostate volume measured by 
transrectal ultrasound into the model was studied. The laboratory based model included 
age and the kallikrein panel while the clinical model included age, tPSA, DRE and 
prostate volume. The models had AUCs of 0.766 and 0.763, respectively, for prostate 
biopsy outcome in Rotterdam and 0.809 and 0.774 in Göteborg (Table 10) The AUCs for 
predicting high-grade cancer were slightly higher than for any cancer in the Rotterdam 
cohort and slightly lower in the Göteborg cohort. Adding clinical measures to the 
kallikrein panel increased the predictive accuracy but the increase was statistically 
significant only in the Rotterdam cohort (Table 11). 
Furthermore, the correlations of the full model and the individual markers with prostate 
volume were studied. The full model showed a correlation of 0.60 and 0.57 (Spearman's 
rank correlation coefficient) in the Rotterdam and Göteborg cohorts, respectively. Of the 
individual markers, fPSA-N had the highest correlation of 0.55 and 0.41 in the Rotterdam 
and Göteborg cohorts, respectively (Table 12). 
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Table 10. Predictive accuracy for prostate cancer of models built on the training set and 















A Kallikrein panel  
(age, tPSA, fPSA, fPSA-I, thK2) 0.766 0.847 0.809 0.786 
B Clinical model  
(age, tPSA, DRE, TRUS volume) 0.763 0.846 0.774 0.681 
C Full laboratory model:  
Kallikrein panel (A) + DRE 0.778 0.856 0.810 0.802 
D Laboratory plus clinical model: 
Kallikrein panel (A) + DRE + TRUS 
volume 
0.792 0.860 0.826 0.802 
 
Table 11. Comparison of the differences in predictive accuracy between the models  















A vs. B -0.003 (p=0.8) -0.001 (p=1) -0.035 (p=0.3) -0.105 (p=0.2) 
C vs. A 0.012 (p=0.033) 0.009 (p=0.17) 0.001 (p=0.9) 0.016 (p=0.3) 
C vs. B 0.015 (p=0.15) 0.010 (p=0.075) 0.036 (p=0.3) 0.121 (p=0.3) 
D vs. C 0.014 (p=0.002) 0.004 (p=0.2) 0.016 (p=0.14) 0.000 (p=0.9) 
 
Table 12. Correlation between TRUS volume and kallikrein isoforms. The analyses were 









Kallikrein panel 0.60 0.57 
fPSA-N 0.55 0.41 
fPSA 0.53 0.51 
N/T PSA 0.46 0.39 
fPSA-I 0.44 0.36 
F/T PSA 0.43 0.48 
thK2 0.33 0.19 
tPSA 0.21 0.15 
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5.4 Development of the fPSA-N immunoassay (IV) 
5.4.1 Analytical performance 
The fPSA-N and fPSA(2C1) immunoassays had a common standard curve because intact 
proPSA was used as the calibrator. This and the standard curve for tPSA(2C1) assay are 
shown with precision profiles (mean of five different runs) in Figure 11. The blocking 
efficiency of Mab 4D4 in the fPSA-N assay was calculated as average of six calibrator 
dilutions in five different runs and it was a stable 88% at the linear range of the assay 
(0.059–55 ng/mL). To correct the fPSA-N concentrations for the 12% cross-reaction with 
fPSA-I the measured fPSA-N concentrations were multiplied with the correction factor 
0.88.  
 
Figure 11. Standard curves (closed symbols) and imprecision profiles (open symbols) for 
fPSA(2C1) and fPSA-N assays (rectangle) and tPSA(2C1) assay (square) (IV). The same 
standard curve was used for both fPSA(2C1) and fPSA-N assays due to standardization 
with intact proPSA. Blocking efficiency of fPSA-N assay at different proPSA 
concentrations is shown with X. 
 
The assay performance characteristics for the developed fPSA-N, fPSA(2C1) and 
tPSA(2C1) and optimized fPSA-I assay are shown in Table 13. The calculation of the 
analytical and functional detection limits for the fPSA-I assay and for the previously 
reported fPSA and tPSA assays are based on measurements reported in publication II. The 
detection limits of fPSA-N and fPSA(2C1) assays were close to the detection limit of the 
optimized fPSA-I assay. The detection limits of tPSA(2C1) assay were close to the 
















































fPSA & fPSA-N CV%
tPSA CV%
Blocking efficiency %
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Table 13. Assay performance characteristics for the developed fPSA-N, fPSA(2C1) and 
tPSA(2C1) assay and optimized fPSA-I assay as well as, for comparison purposes, for 











fPSA-N IV 0.016 0.100 95.0  (89.6–145.3c) 
fPSA(2C1) IV 0.016 0.100 90.7 (84.7–101.4) 
tPSA(2C1) IV 0.006 0.05 94.8 (87.9–108.1) 
fPSA-I II , IV 0.01d 0.13 84 (75–96)e 
fPSA II , unpublished 0.006f 0.03e N.D.g 
tPSA II , unpublished 0.006f 0.03f N.D. 
a det. lim., detection limit, calculated as mean of calibration diluent + 2SD 
b det. lim., detection limit, estimation of lowest concentration with CV% < 20% 
c A single sample of the five samples measured  
d  Originally reported analytical det. lim. 0.035 ng/mL (Nurmikko et al., 2001)  
e in serum, from (Nurmikko et al., 2001)  
f Originally reported analytical det. lim. 0.01 ng/mL and functional det. lim. < 0.1 ng/mL 
(Lerner et al., 1996) 
g N.D., no data 
 
5.4.2 Detection of different seminal plasma PSA isoforms 
Five seminal plasma PSA pools containing differing proportion of intact and nicked PSA 
(Zhang et al., 1995) were measured with fPSA-N, fPSA(2C1) and tPSA(2C1) assays to 
ensure that the fPSA-N assay measures nicked PSA as specifically as expected. The ratios 
of fPSA-N and fPSA to tPSA are shown in Figure 12. Pools A and B were reported to 
contain only intact PSA, pools C 20% and D  10% of intact PSA, and pool E only 
approximately 5% of intact PSA. 




Figure 12. Proportion of fPSA (circle) and fPSA-N (square) to tPSA in seminal plasma 
PSA pools (IV). 
5.4.3 fPSA forms in clinical material 
The different PSA forms (fPSA-N, fPSA-I, fPSA and tPSA) were at or below the 
analytical detection limit in all 12 samples from healthy female volunteers. The 
concentrations and interquartile ranges of the markers for 9 healthy male volunteers,  
27 patients with benign prostate condition and 49 prostate cancer patients are shown in 
Table 14.  
Table 14. Median and interquartile range (IQR) of different PSA forms and their ratios in 
healthy males and patients with benign disease and prostate cancer (IV, unpublished). 
The markers were measured with the new assays developed in study IV, except for fPSA-I 




n = 9 
Benign disease 
n = 27 
Cancer 
n = 49 
tPSA (ng/mL) 0.649 (0.432–0.821) 10.34 (4.375–19.56) 5.464 (4.728–10.743) 
fPSA (ng/mL) 0.247 (0.151–0.283) 1.385 (0.651–2.771) 0.855 (0.628–1.761) 
fPSA-N (ng/mL) 0.050 (0.033–0.064) 0.420 (0.153–0.786) 0.239 (0.131–0.452) 
fPSA-I (ng/mL) 0.176 (0.09–0.205) 0.478 (0.284–0.606) 0.550 (0.351–0.914) 
    
F/T PSA (%) 38.5 (35.2–40.8) 19.7 (14.2–27.3) 14.7 (12.4–22.9) 
N/T PSA (%) 7.8 (6.8–9.2) 5.1 (4.0–7.2) 3.4 (2.3–4.7) 
I/T PSA (%) 27.1 (24.9–27.9) 5.5 (2.8–9.9) 9.4 (6.3–13.0) 
N/F PSA (%) 19.9 (18.1–22.4) 27.6 (23.4–36.3) 24.2 (17.4–31.9) 
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5.4.4 Comparison of the new assays to previously used methods 
In all previous studies the concentration of fPSA-N was calculated by subtracting fPSA-I 
concentration from fPSA concentration. The calculated and directly measured fPSA-N 
concentrations of the 76 patients are plotted in Figure 13A. Furthermore, the fPSA and 
tPSA concentrations measured with previously published and new methods in these 
patients are plotted in Figure 13B and C. The Deming (model II) regression lines and 
corresponding equations are also shown in the figures. 
The measured fPSA-N concentrations were on average 91% of the calculated values  
(SD 64%, median 77%, interquartile range 62–96%). fPSA(2C1) concentrations were on 
average 128% of the concentrations measured with previously used fPSA assay (SD 51%, 
median 112%, interquartile range 95–145%) while the tPSA(2C1) assay gave a result 
which was on average 75% of the result from the previously used tPSA assay (SD 14%, 
median 73%, interquartile range 67–82%).  




Figure 13. Comparison of the new assays and previously used methods (IV, 
unpublished). Concentrations were measured from 79 samples of men with benign or 
cancerous prostate condition. Concentrations from different methods are compared by 
Deming (model II) regression (line and equations). A) fPSA-N concentrations determined 
by directly measuring with the new fPSA-N assay or by calculation (fPSA minus  
fPSA-N). B) fPSA concentrations measured with the new fPSA(2C1) or with the 
previously used assay (see chapter 4.3.3). C) tPSA concentrations measured with the new 





6.1 Immunoassays and their performance 
Assay interference is a recognized problem for immunoassays and has caused some 
unfortunate cases of misdiagnosis and unnecessary treatments (Cole et al., 1999; Fritz et 
al., 2009; Ismail et al., 2002). The interference caused by different antibody-binding 
molecules in the sample component is often decreased by adding scavenger 
immunoglobulins to which the proteins should bind instead of the assay antibodies. Even 
though the results have been good and the scavenger antibodies are used as blocking 
agents in most immunoassays they do not remove the interference completely. 
The prevalence of the assay interference is strongly dependent on the assay construct and 
the population in question. Despite the use of scavenger antibodies in the assay buffers, 
our original fhK2 and fPSA-I assays suffered from falsely elevated signals in some 
samples causing the ratios of F/T hK2 and I/F PSA to be above 1, which is impossible by 
definition (Nurmikko et al., 2001; Vaisanen et al., 2004; Vaisanen et al., 2006). When 
1092 random female and 957 male heparin plasma samples were measured with fPSA-I or 
fhK2 assays with previously published protocols bovine IgG as the only blocking agent 
there were falsely elevated signals in 10–40% of the samples (I). These rates are within 
the published range of observed interference rates (see Chapter 2.4.1 for more 
information) even though they are at the upper end of the range. It is notable that this 
initial screening was done in singlicates which increases the possibility that assay 
variation explains part of the falsely elevated signals. 
Many of the antibody-binding interfering factors are more likely to bind the Fc part of the 
antibody molecule and thus, removing the Fc part has been previously used to successfully 
reduce interference problems (Bjerner et al., 2002; Vaidya and Beatty, 1992). In our 
assays, changing the capture or tracer Mab to Fab- or F(ab')2-fragment and adding 
denatured mouse IgG to the assay buffer practically removed or significantly reduced the 
interference (0–6% of samples exhibiting falsely high signals).The magnitude of the false 
elevation of the signals was decreased as well. The effects were also seen in large patient 
sample cohorts measured with the optimized assays. 
The original assays have been used to measure many sample panels (Niemelä, 2002; 
Nurmikko et al., 2001; Steuber et al., 2005; Vaisanen et al., 2004; Vaisanen et al., 2006; 
Vickers et al., 2008) and the interference may have affected the results. If the prevalence 
of interfering samples is assumed to be approximately the same in different patient groups 
(healthy subjects as well as patients with benign conditions and cancer) the presence of 
interference samples might weaken the association between the markers and prostate 
cancer and thus cause underestimation of the markers' clinical value. The effect would 
probably be minor when large panels are measured. However, there is a possibility that the 
prevalence of the assay interference does differ between the different patient groups. This 
is not very likely, though, as the results based on the studies using the kallikrein panel 
show: the overall discrimination was similar in cohorts measured with original and 




Vickers et al., 2010c). A smaller-scale study (unpublished) in which the original and 
optimized assays were used to measure four sample groups with different tPSA range and 
F/T PSA ratios (n = 100 in each) shows similar results. The effect of the change in the 
assay format was minor in each group (results not shown).  
A novel observation was that in some samples the blocking antibodies caused a signal 
elevation instead of a decrease. Even though this was clearly more common when the 
blocking antibodies were in native form we cannot exclude the possibility that the 
denatured mouse IgG could also cause false signal elevation in some samples. 
Alternatively, it is possible that there might have been negative interference in some 
samples, in which the signals were elevated in the optimized assay but remained at a 
"logical level". This is difficult to confirm but, if true, could be seen as a desired 
correction to the result. 
The optimized fPSA-I assay had better analytical and functional detection limits than the 
original assay because the recombinant Fab fragment used as the capture antibody is 
smaller allowing more dense binding to the streptavidin surface and thus higher antigen 
binding capacity. Furthermore, the site specific biotinylation enables these fragments to 
bind to the streptavidin surface in a functional orientation further increasing the capacity. 
This caused an increase in the signal to background ratio and lead to improved detection 
limits in the fPSA-I assay. The improved assay performance was also seen in the 
kallikrein panel when it was applied to recently screened men in both Göteborg and 
Rotterdam cohorts (Vickers et al., 2010c). The samples from Göteborg were measured 
with the original assays and the Rotterdam samples with the optimized assays. The 
predictive accuracy associated with fPSA-I was increased when the optimized assay was 
used. However, the optimized fhK2 and thK2 assays, based on enzymatically cleaved 
F(ab')2-fragments, had similar detection limits as the previously used assay protocols 
(results not shown) and thus the improvement in assay performance in terms of fewer 
samples with interference may not be as direct and visible as with fPSA-I assay. 
The assay interference observed in the fPSA-I assay suggested that the fPSA-N and 
fPSA(2C1) assays (IV) might be prone to similar interference problems. Indeed, it was 
found that using the recombinant Fab as capture antibody instead of Mab and adding the 
denatured mouse IgG into the assay buffer were also necessary for these two assays. For 
consistency, the same assay buffer was used in the tPSA(2C1) assay too, even though the 
capture antibody was Mab in this assay. The analytical and functional detection limits of 
the fPSA-N and fPSA(2C1) assays were comparable to the fPSA-I assay's detection limits 
and the tPSA(2C1) detection limits were also close to the detection limits of the 
previously published tPSA assay. 
In the fPSA-N assay, the unique Mab 4D4 which recognizes PSA without the internal 
cleavage at Lys145/Lys146 was used as a blocker antibody to inhibit the binding of the 
tracer Mab 2C1 which has an overlapping epitope. The blocking was stable: 88% of the 
fPSA-I signal was blocked. The reasons for imperfect blocking may be that the epitopes 
are not completely mutually exclusive and that the affinity of 4D4 is slightly low due to 




To compensate for the lower affinity 4D4 was used in large excess. Increasing the amount 
further might improve the blocking efficiency but it was considered impractical as the 
consumption of the antibody would have been too high. 
The concentrations measured with the new assay methods were compared to the 
concentrations measured from the same patient samples with the previously used methods 
by Deming regression analysis. The fPSA-N assay gave concentrations that were 
generally lower than the calculated concentrations. Based on the regression line slope 
(1.23) and the y-axis intercept (close to 0), the difference between the methods seem to be 
proportional rather than constant. This is most likely due to differences in assay 
constructions (for example antibody combinations and assay protocols) which are known 
to affect assay results as discussed in chapter 2.4.2 (Kort et al., 2006; Stephan et al., 
2006b). Furthermore, it is theoretically possible that there are differently cleaved or other 
kinds of fPSA forms which are not recognized by either fPSA-N or fPSA-I assay but are 
measured by fPSA assay. Whether this observed difference in measured and calculated 
concentrations has any clinical impact remains to be seen in the comparative studies to be 
performed in the future. 
In order to obtain fPSA and tPSA concentrations comparable to fPSA-N concentrations 
new assays with equal protocols and only the minimal necessary changes in the capture or 
tracer antibodies were developed. The new fPSA(2C1) and older fPSA assays seemed to 
agree rather well based on the Deming regression analysis as the slope was 1.03 even 
though the differences in some individual samples were high. The tPSA concentrations 
measured with the new tPSA(2C1) assay were lower than the concentrations measured 
with the previously used assay method (slope 0.86) emphasizing a need for the new assay 
to gain comparable results. As stated, the differences in antibody combinations and assay 
constructions are the probable reasons for the disagreement between the old and new 
methods. 
The specificity of the fPSA-N assay was as expected because the measured fPSA-N 
proportions of five seminal plasma pools containing different amounts of intact and nicked 
PSA were similar to previous results (Nurmikko et al., 2000; Zhang et al., 1995). 
However, the pools D and E showed somewhat lower proportions of fPSA-N than 
expected which may be due to the presence of PSA forms unrecognizable to our 
immunoassay (Mattsson et al., 2008). 
In the future, the fPSA-N assay should be standardized with pure nicked PSA standard 
material. The development of a purification method for fPSA-N is ongoing. As the assay 
method is rather complicated and long, it should be streamlined. To redesign the assay the 
binding affinity of the 4D4 antibody needs to be improved. One way to achieve this is to 
develop 4D4 Fab fragment and genetically engineer the binding site of the Fab to exhibit 
slower off-rate for dissociation from the antigen. This process has been started and results 
are expected within the next year. Another option is to develop an fPSA-N specific binder 




6.2 Concentrations of fPSA forms and thK2 in blood 
samples 
Because the optimized assays were used to measure the clinically defined radical 
prostatectomy patient samples for the first time in this study it is of interest to compare 
these concentrations of fPSA forms and hK2 in blood circulation to the previously 
reported values. In the different cohorts, the median fPSA-I concentration in non-cancer 
patients was between 0.36 and 0.49 ng/mL (III, IV) and between 0.41 and 0.55 ng/mL in 
cancer patients (II–IV). The previously reported median values for fPSA-I measured with 
original assays are 0.39–0.43 for non-cancer patients and 0.47–0.49 for cancer patients 
(Nurmikko et al., 2001; Steuber et al., 2005; Steuber et al., 2002; Steuber et al., 2007a). 
The median calculated fPSA-N concentration in non-cancer patients was between 0.35 
and 0.54 ng/mL (III, IV) while the concentration in cancer patients was 0.24–0.43 ng/mL 
(II–IV). Despite the variation between different sample panels, these results are almost 
within the same range with previously published results showing median concentration 
range of 0.41–0.53 ng/mL for non-cancer patients and 0.34–0.50 ng/mL for cancer 
patients (Nurmikko et al., 2001; Steuber et al., 2005; Steuber et al., 2002; Steuber et al., 
2007a).  
The proportions of different fPSA forms in the total fPSA fractions are interesting as the 
combinations of the subforms and fPSA seem to bring new information about the prostate 
status. In men without cancer 47% of fPSA was fPSA-I and 53% was fPSA-N (calculated 
concentrations) in the Rotterdam cohort (III, unpublished). The proportions for fPSA-I 
and fPSA-N in men with a benign disease were 29% and 28%, respectively, when the 
fPSA-N concentrations were directly measured in another smaller sample set (IV). It is 
interesting that in the latter cohort the proportions of fPSA-I and fPSA-N do not add up to 
100%. Whether this is caused by assay differences or the theoretical fPSA forms that our 
assays for fPSA-I and fPSA-N may not recognize but the assay for tPSA recognizes, 
remains unclear. The latter is possible because of the variety of the reported PSA isoforms 
for example in seminal plasma (Mattsson et al., 2008). The Rotterdam cohort proportions 
are calculated with the older, established fPSA assay and the latter with the new 
fPSA(2C1) assay but as these two assays showed rather good agreement the differences in 
fPSA measurement may not be the main reason for fPSA-I and fPSA-N not adding up to 
100% of fPSA.  
In cancer patients the median proportion of fPSA-I from fPSA was 56–65% (II–IV, 
unpublished) while the proportion of calculated fPSA-N concentration was 40–44% (II, 
III). When the proportion of the directly measured fPSA-N (24% in IV), and the median 
fPSA-I concentration in the same cancer patients are added up the result is 88% which is 
closer to the 100% of total fPSA than in patients with a benign disease where fPSA-N and 
fPSA-I comprised 57% of fPSA. The properties of the fPSA-N measurement may be one 
probable cause for this: the blocking may work proportionally on samples containing 
different amounts of fPSA-I even though it seems to be stable with different 
concentrations of standard material. This question should be addressed in the future when 




The median concentration of thK2 is 0.075–0.085 ng/mL in the cancer patients of the 
Rotterdam and Göteborg cohorts (III). This is in accordance with previously published 
median concentrations of cancer patient samples (0.065–0.105 ng/mL) which were 
measured with the original (or a similar) immunoassay method (Steuber et al., 2007a; 
Vaisanen et al., 2004; Vaisanen et al., 2006; Vickers et al., 2007). In the men without 
cancer the median thK2 concentrations were 0.045–0.067 ng/mL. This is in the same 
range as previously reported values which were between 0.037–0.093 ng/mL for men 
without cancer (Steuber et al., 2005; Steuber et al., 2007a; Vickers et al., 2007).    
6.3 Clinical significance of fPSA and hK2 forms 
Diagnosing and treating patients with indolent prostate cancer which is not likely to cause 
any harm to the patient, in other words over-diagnosis and overtreatment, are problems 
that cause not only unnecessary anxiety, discomfort and a risk of side-effects for the 
patient but also significant costs to the healthcare systems (Schroder et al., 2009). One of 
the main research questions during the last few years has been how to detect the 
aggressive cases of cancers that need to be treated and leave the indolent cases to be 
detected only until they later become significant, if they ever do. 
Previous studies have compared the fPSA-I concentrations in patients with prostate cancer 
and benign prostatic hyperplasia with results indicating that fPSA-I seems to be more 
closely related to cancer than to BPH (Nurmikko et al., 2001; Steuber et al., 2005; Steuber 
et al., 2002) and that it could aid in the discrimination of these two patient groups.  
Of note, the fPSA-I measured with our immunoassay includes also proPSA isoforms 
(Mikolajczyk et al., 2004) of which especially [-2]proPSA (or p2PSA) has been associated 
with cancer tissue (Mikolajczyk et al., 2004; Mikolajczyk et al., 2001). The p2PSA has 
been included in the Beckman-Coulter prostate health index phi (Le et al., 2010) and a 
recent study by Guazzoni et al. suggest that p2PSA and its derivatives, including phi, 
might help in predicting the prostate cancer pathology (Guazzoni et al., 2012).  
In comparison, study II was the first one to examine the association of the fPSA-I and 
fPSA-N concentrations with pathological cancer stage and grade to address their possible 
usefulness in predicting the cancer aggressiveness. Although the correlations were not 
strong, a trend showing F/T PSA, N/T PSA and I/T PSA ratios to be lower in patients with 
more adverse cancer pathology was found to exist. Because tPSA also correlates with the 
pathological stage and grade it is possible that it has major contribution to the correlation 
of the different ratios, especially with TNM stage and WHO grade. It is notable that in 
patients with tPSA < 10 ng/mL fPSA-N, as a single marker, correlated with Gleason score 
and was significantly lower in patients with high grade cancer than in patients with lower 
grade cancer, irrespective of how the patients were divided into different groups by the 
Gleason grade. Thus, it is likely that fPSA-N and, because of the calculation used, fPSA-I 
have an independent contribution to the correlation of the above mentioned ratios and 
Gleason grade as well as to their ability to separate different Gleason grade groups. In 




cancer in this patient group but most likely it would have to be combined with other 
biomarkers or clinical information to reach clinical significance. 
The concentrations of different PSA forms overlapped in different groups based on 
pathological stage or grade and, therefore, the single markers did not have prediction of 
cancer pathology in an individual patient. However, as the above mentioned ratios were 
statistically different between some of the groups the markers might work as a 
combination in a statistical model. Several different models have been created for both 
prognostic and predictive use, as discussed in chapter 2.5 (Gosselaar et al., 2008; Kranse 
et al., 2008; Makarov et al., 2007; Roobol et al., 2012; Schroder and Kattan, 2008; Shariat 
et al., 2008; Steyerberg et al., 2007).  
However, we did not create a model based on the radical prostatectomy patient data 
because we did not have enough follow-up data of the patients to evaluate the model nor 
did we have access to other pre-clinical data such as the clinical stage or biopsy grade 
making the comparison with currently used methods difficult. Furthermore, the number of 
patients was not quite high enough for creating and validating such a model. 
A statistical model was developed to predict biopsy outcome in men with elevated PSA 
and participating the European Randomized Study of Screening for Prostate Cancer, or 
ERSPC (Vickers et al., 2010a; Vickers et al., 2008; Vickers et al., 2010b; Vickers et al., 
2010c). The biopsy is uncomfortable to the patient, increases the risk of infections and 
other side-effects (Loeb et al., 2011; Nam et al., 2010) and obviously increases the costs 
to the healthcare system, therefore, avoiding the unnecessary biopsies would benefit both 
the patient and the healthcare system. The model was based on the measurements of tPSA, 
fPSA, fPSA-I and thK2 – also called as the kallikrein panel – from serum samples. The 
model was shown to potentially reduce the number of unnecessary biopsies by 49–60% in 
men without recent screening and 30-40% in recently screened men when a cut-off of 
20% cancer risk was used as a threshold for biopsy. The few cases of cancer missed were 
mostly low-grade cancers typically considered to be over-diagnosed. 
In study III, the aim was to add information about prostate volume to the kallikrein model 
and study its effect on the model's predictive accuracy in previously unscreened men with 
indication for biopsy. The combination of prostate volume and serum tPSA concentration 
has been associated with prostate cancer risk in several studies (Catalona et al., 2000; 
Epstein et al., 1994; Freedland et al., 2005). Whether any of the kallikreins or their 
combinations could replace the volume measurement was also of interest. The volume 
measurement is acceptable to most men but some find it uncomfortable (Aus et al., 1993; 
Djavan et al., 2001). It requires some expertise (Ko et al., 2011) to be reproducible and a 
visit to the urologist is also necessary. Money and time would be saved if the volume 
measurement could be replaced with a blood draw. 
Indeed, the kallikrein model (including age, tPSA, fPSA, fPSA-I and thK2) was equally 
accurate to the clinical model (including age, tPSA, DRE, TRUS volume) in predicting 
prostate cancer in biopsy. The predictive accuracy was expressed as AUC (see chapter 




kallikrein panel in the Rotterdam and Göteborg cohorts, respectively. When the TRUS 
volume was included in the full laboratory model (kallikrein panel and DRE) the 
increment of AUC was 0.014 or 0.016 (in the Rotterdam and Göteborg cohorts, 
respectively) which is considered very small even though it was statistically significant in 
the Rotterdam cohort. Results were essentially similar when high-grade cancer was 
predicted, further supporting the kallikrein panel's ability to replace prostate volume in 
this predictive model. 
Our hypothesis was that especially fPSA-N might correlate with prostate volume because 
Steuber et al. had previously shown that in a linear regression model fPSA and fPSA-N 
were the most important predictors for prostate transition zone volume (Steuber et al., 
2005). The fPSA-N correlated moderately with prostate volume (Spearman's correlation 
coefficient 0.55 and 0.41 in the Rotterdam and Göteborg cohorts, respectively) fPSA-N 
having the best correlation of the single markers in the Rotterdam and second best in the 
Göterborg cohorts. Our results are supported by a study in which another internally 
cleaved free PSA isoform BPSA was found to correlate with prostate volume as well as 
transition zone volume independent of age (Spearman's correlation coefficient of 0.63 and 
0.64, respectively) (Canto et al., 2004). In another study, BPSA and the ratio of BPSA to 
proPSA were also found to help in distinguishing prostate cancer patients from men 
without cancer in men with F/T PSA < 15 % as well as in men with tPSA within the range 
of 4–10 ng/mL (Khan et al., 2004).  
The presence of cancer is unlikely to effect the correlation based on a preliminary 
correlation analysis with the Rotterdam cohort (Pearson's correlation coefficient of log-
transformed concentrations of the antigens). The correlation coefficients were similar 
between the men with and without cancer (results not shown). tPSA and thK2 correlation 
coefficients had the largest differences between the groups so that the correlation 
coefficients were higher for the non-cancer group (0.367 vs. 164 for tPSA and 0.45 vs. 
0.267). In order to study the effect of cancer to the volume correlation of each antigen  
a regression analysis should be done but, unfortunately, that was not within the timeframe 
of the current study. 
The fPSA-I, as a more cancer related marker (Nurmikko et al., 2001; Steuber et al., 2002), 
was not expected to correlate strongly with prostate volume. Another recent study by 
Guazzoni et al. suggest that the ratio of p2PSA to fPSA and phi might help in predicting 
the prostate cancer in the initial biopsy (Guazzoni et al., 2011). Overall, the studies with 
different free PSA forms support each other by indicating that they probably would help 
both in estimating the cancer risk before the initial biopsy and in estimating the cancer 
aggressiveness preoperatively. However, they are most beneficial when used in 
combination with other markers, usually with tPSA and fPSA or with some clinical data 
such as age, DRE or prostate volume. 
The biology behind the different PSA forms in circulation is not clear but it has been 
hypothesized that the PSA leaked from the BPH cells is exposed to proteases and thus 
cleaved in the extracellular matrix before diffusion into the circulation. The cleavages 




hand the PSA in cancer tissues might diffuse faster into circulation due to the distorted 
structure of the cancerous tissue and it is less processed. (Balk et al., 2003; Chen et al., 
1997; Stenman, 1997.) This would explain the lower proportion of fPSA in cancer 
patients' circulation as well as the higher proportion of intact fPSA forms. The volume 
dependency of the PSA concentrations could be explained by the increased number of 
epithelial cells in BPH tissue and by the observation that PSA secretion of cancerous cells 
may actually decrease (Schalken, 2004). 
hK2 has been shown to be valuable in the kallikrein panel even though its significance 
may not be as great as that of the combination of fPSA and fPSA-I (Vickers et al., 2010a; 
Vickers et al., 2008; Vickers et al., 2010c). Because in many studies hK2 has been 
associated with tumor volume or cancer aggressiveness  it may bring additional 
information regarding the cancer status (Haese et al., 2003a; Haese et al., 2003b; Haese et 
al., 2005; Steuber et al., 2005). 
Roobol et al. suggested that the prostate cancer risk calculator (www.prostatecancer-
riskcalculator.com, discussed in chapter 2.5.2) which has been developed based on the 
ERSPC data (Kranse et al., 2008; Steyerberg et al., 2007) should contain information 
about the prostate volume whether measured by TRUS or estimated during the DRE 
(Roobol et al., 2012). The authors suggest that the DRE-based estimation could be used to 
make the use of the risk calculator easier. It might be possible to replace the volume 
estimation by the measurement of the kallikreins, which would make the use of the 
calculator even easier because, instead of inviting the patient to visit a urologist, the 
sample could be sent to a further analysis and the costs of a clinical visit would be 
replaced by the costs of the immunoassays. It has been estimated that the kallikrein assays 
would add less than $100 (approximately 75 €) to the cost of testing the tPSA alone 
(Vickers et al., 2008). 
So far it has not been sensible to study the combination of fPSA-I and fPSA-N in  
a statistical model like Khan et al. have done with proPSA and BPSA (Khan et al., 2004) 
because the use of calculated fPSA-N concentrations. The calculated fPSA-N 
concentrations are interdependent of the fPSA and fPSA-I concentrations and thus the 
information of fPSA-N is already included in the model if the two other concentrations are 
used. Once the direct fPSA-N immunoassay (IV) has been optimized for large scale 
measurements the relevance of the combination of fPSA-I and fPSA-N is obviously one of 
the most interesting thing to be studied.  
Taken together, the growing number of studies are indicating that internally cleaved fPSA 
forms (fPSA-N, BPSA) are related to the benign volume of the prostate whereas the intact 
forms (fPSA-I, proPSA) are more likely related to the presence of cancer. It would be of 
great interest to study the presence of these forms side-by-side in the very same samples 
(for example blood samples or tissue lysates from the prostates) to better understand the 
bigger picture of fPSA forms. They may tell the same story or they may offer independent 
information regarding the biology behind prostate diseases. Combining the stories might 





As the systematic PSA based screening for prostate cancer seems to result in over-
diagnosis and overtreatment (Schroder et al., 2009), the search for new and better markers 
for identifying the potentially aggressive types of cancer has been intensive.  
Despite that some scientists declared already in 2004 that the "PSA era is over" (Stamey et 
al., 2004) and the fact that PSA is not cancer specific, it still remains the most important 
prostate cancer marker. The current trend to combine the information of different isoforms 
of PSA and possibly some of the newer markers has consolidated the position of PSA also 
as the future marker for one of the most common types of cancer in the Western world. 
This study focused on the measurement of intact and nicked PSA isoforms and free and 
total hK2 in different clinical settings. The main conclusions based on the original 
publications are: 
I The assay interference observed in the fPSA-I and fhK2 immunoassays was 
significantly reduced by using recombinant Fab or enzymatically produced F(ab')2 
fragments instead of intact monoclonal antibodies in the assays. Furthermore, the 
heat-denatured mouse IgG was found to be the best blocking agent and it was 
added to the assay buffer to supplement the bovine IgG used as a regular 
component in the buffer. The assay redesign did not have any negative effects on 
the analytical performance of the assays.  
II The measured fPSA-I and calculated fPSA-N preoperative concentrations as well 
as their proportion to tPSA were found to be associated with pathological Gleason 
grade of the prostate cancer in radical prostatectomy patients, especially in the 
patients with tPSA concentrations below 10 ng/mL. The strength of the 
association was moderate. The association of the markers with pathological stage 
or WHO grade may not be independent of tPSA contribution. Further studies with 
follow-up data on the patients are needed to clarify the relevance of the isoforms 
for predicting cancer pathology. 
III The kallikrein panel including age, tPSA, fPSA, fPSA-I and thK2 could predict 
the biopsy outcome equally well to the clinical model including age, tPSA, DRE 
and TRUS volume in unscreened men with indication to biopsy. The kallikrein 
panel could be considered to replace the volume measurement in prostate cancer 
risk estimations. Furthermore, the calculated concentration of fPSA-N was found 
to correlate with the prostate volume as a single marker.  
IV An immunoassay for direct measurement of fPSA-N was developed and 
evaluated. The assay was specific and had an acceptable analytical and functional 
performance. The slightly complicated assay method needs further optimization 
and the standardization should be done in the future with fPSA-N instead of 




In conclusion, the use of PSA measurement is shifting from single tPSA measurement 
towards multimarker measurements combining the information from several serum 
markers with clinical information, most likely in a statistical model. The free PSA 
isoforms fPSA-I and fPSA-N seem to contain information additional to total PSA and 
when combined to hK2 it is possible to estimate the prostate cancer risk even more 
accurately. The future studies should be able to show whether the kallikrein panel could 
be used in other clinical settings, for example, to aid in estimating the prognosis after 
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